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ABSTRACT 
Background: The declining levels of estrogen and progesterone during the menopausal 
transition predispose women to an increase in overall body mass and altered adiposity distribution 
that may place them at risk for developing cardiometabolic disease. Estrogen, progesterone and 
testosterone levels have been linked to changes in lipid metabolism and since these hormone 
levels change during the menopausal transition they may contribute to the unfavorable alteration 
in body composition. Differences in fat oxidation rates (FOR) have been observed between 
ethnic groups and the hormonal modifications that occur after menopause have been speculated to 
influence these differences. Only select ethnic groups have been studied, and exploring 
additional groups will allow further understanding of the menopausal transition and FOR. 
Purpose: The purpose of this study was to compare resting FOR, FOR during incremental 
exercise and FORmax, hormone levels, anthropometric characteristics, physical activity (PA) levels 
and cardiometabolic risk factors between Middle Eastern (ME) and W postmenopausal women. 
Results: Significant differences between groups were observed are as follows; the ME women 
were younger (p= 0.004), observed their first period at an earlier age (p= 0.023) and had their last 
menstrual cycle early in life (p= 0.031). Time since first and last cycle was shorter in the ME 
group (p= 0.007). ME had a higher body mass (p= 0.027), a higher body mass index (p= 0.32) 
and a larger waist circumference (p= 0.005). W women had a higher peak aerobic capacity 
(p=0.003) and higher self-reported levels of PA (p=0.017). 
Discussion: The ME women did not exhibit lower FOR at rest, during incremental exercise or at 
maximum exercise and ME women did not have a lower level of estrogen or have more 
cardiometabolic risk factors than the W women. This study sheds light on FOR within a new 
ethnic group of postmenopausal women not yet investigated. As well, data on FOR, FORmax and 
the exercise intensity expressed as a percentage ofV02 peak, at which maximal fat oxidation 
occurs using a treadmill protocol and hormonal measurements for ME and W postmenopausal 
ii 
women. A treadmill protocol was created and used which provided whole-body FOR at multiple 
sub-maximal PA intensities. PA levels and anthropometrics were also obtained in this study 
providing detailed data on the health and fitness characteristics of the study populations. 
iii 
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1.0 INTRODUCTION 
The menopausal transition has been speculated to predispose women to comorbidities 
that are obesity-related thereby increasing the risk of cardiometabolic diseases (Carr, 2003; 
Sowers et al. 1995; Barrett-Connor 1993; Price et al. 1998). Changes in estrogen, progesterone, 
testosterone and other associated hormone levels during the menopause transition have been 
linked to increasing the risk of cardiometabo lie diseases ( G lendy et al 193 7, Barrett-Connor et al. 
1991, Brezinika and Padoms, 1994, Carr, 2003). Increased abdominal adiposity post menopause 
is the most prominent physiological change observed (Price et al. 1998), a feature that is 
speculated to promote increased cardiometabolic risk in aging women. Estrogen, progesterone 
and testosterone levels have been reported to influence substrate metabolism and more 
specifically fat metabolism at both rest and during exercise (Zarins et al.2010). As these hormone 
levels change during the menopausal transition they may be contributing to the increase in overall 
body mass and visceral adiposity distribution observed post menopause. Fat oxidation rates 
(FOR) at rest and during exercise have been noted to decrease though the menopausal transition 
and therefore the decrease in estrogen has been associated to decreases in FOR at rest and during 
physical activity (PA) (Santa-Clara et al. 2006; Rickner et al. 2001). In addition, differences in 
hormones levels (Setaiwan et al. 2006, Randolph et al. 2004) and FOR (Hall et al. 2010) have 
been observed among White, African American, European and South Asian ethnic groups. Select 
ethnic groups have been studied, but there are gaps in the literature. Although over 70% of 
postmenopausal Iranian women are reported to be abdominally obese there have been no studies 
of their hormonal and FOR characteristics during exercise. Therefore, in the present study, FOR 
at rest and during exercise in Middle Eastern (ME) and White (W) postmenopausal women will 
be examined. 
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2.0 LITERATURE REVIEW 
2.1 MENOPAUSAL TRANSITION 
The reproductive system of a female undergoes significant stages of change or 
transitional periods or phases during the course of life, which has been speculated to influence her 
physiology and risk for disease development (Glendy et al. 1937, Barrett-Connor et al. 1991, 
Brezinika and Padmos, 1994, Carr, 2003). A stage of change or transitional period that occurs 
late in life is called the menopausal transition (Burger et al. 2002, Nelson et al. 2005, Sherman, 
2005, Burger et al. 2007), which is broken down into early and late perimenopause, menopause, 
plus early and late postmenopausal stages. The normal reproductive period before the onset of 
the menopausal transition is referred to as premenopause. The overall transitional period is a 
result of ovarian failure and a decrease in estrogen, progesterone and testosterone levels, which 
takes the woman from a state of having menses to the absence of menses (Burger et al. 2002, 
Sherman, 2005, Burger et al. 2007). Each time point of the menopausal transition has its own 
characteristics. 
Perimenopause is the first stage in this transitional period which is characterized by the 
start of irregular and shortened menstrual cycles, increases in follicular stimulating hormone 
(FSH) and lutenizing hormone (LH) levels and the decline of reproductive abilities (Soules et al. 
2001, Nelson et al. 2005, Sherman, 2005, Burger et al. 2007, Elavsky and McAuley 2007), these 
changes continue into the late perimenopause period where these changes continue and menstrual 
irregularities are greater. The time between the final menstrual cycle and up to 12 months post 
the final cycle is still part of the perimenopause stage. Menopause is a point in the transition that 
refers to the absence of cycles for 12 consecutive months (Soules et al. 2001). Menopause can 
only be confirmed and defined after 12 months of amenorrhea following the final menstrual 
period which reflects a near complete reduction of ovarian hormone secretion (Soules et al. 
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2001 ). Menopause is a natural occurrence but it can also be surgically induced through the 
removal of both ovaries (Sherman, 2005). While unique to each woman, the mean age at which 
the menopausal transition begins is 47.5 years and its duration is approximately 5 years (Gosden, 
1985, Nelson et al. 2005). The postmenopausal stage begins after the woman has been in the 
state of amenorrhea for the preceding 12 months or more (Soules et al. 2001, Carr, 2003, 
Sherman, 2005) until her death. An illustration of the menopausal transition is depicted in Figure 
1. 
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Figure I. Illustration of the menopausal transition. 
The symptoms of the menopausal transition include; hot flashes, night sweats, vaginal 
dryness, sleep disturbance, mood symptoms, cognitive disturbances, somatic and urinary 
complaints, abnormal uterine bleeding, sexual dysfunction, and perceived reduced quality of life 
(Nelson et al. 2005; Sherman, 2005). John Leake (1777), a researcher from the late 18th century 
commented on these symptoms as being 'chronic conditions' that only affect the female sex. 
With little knowledge about the menopausal transition and its associated physiology, women were 
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unaware of the changes that were occurring and were unable to understand the process of 
menopause. The physiology of menopausal transition and the associated hormonal changes have 
only been noted in literature since the 1920's (Soules et al 1982). In the nineteenth century 
women did not live to reach the age of menopause, but modem day women spend a third of their 
life in the postmenopausal state (Soules et al. 1982). The symptoms of the menopausal transition 
can vary from woman to woman, from the specific symptoms they experience and the severity of 
the symptoms. The physiological changes during the menopausal transition has only been well 
described in recent years, with research now focusing on the health related implications of the 
hormonal changes during the event. 
2.2 MENOPAUSE TRANSITION AND PHYSICAL ACTIVITY: 
Most investigations focus on the quality of life and the vasomotor symptoms associated 
with menopause and overlook other physiological symptoms. Alterations in PA participation and 
visceral fat accumulation, which also occur during the menopausal transition, may impact the 
overall health of a woman by increasing the prevalence of chronic conditions such as 
cardiovascular disease, hypertension, type 2 diabetes, osteoporosis (Sherman, 2005) and 
metabolic syndrome (Mayes and Watson 2004; Carr, 2003). 
The symptoms of menopause can vary from woman to woman from the specific 
symptoms they experience and the severity of the symptoms. Exercise intervention studies have 
shown the increases in bodily movements can decrease the severity of the menopausal symptoms 
and improve over-all well being (Villaverde-Gutierrezet et al. 2006; Elavsky and McAuley, 2007) 
summary provided in Table 1. Exercise is a sub-category of PA which is bodily movement 
resulting in energy expenditure (EE) varying in intensity (Caspersen et al 1985, Bouchard and 
Shephard, 1994 ). Exercise is planned, structured and has the objective of improving physical 
fitness components which require a threshold intensity to induce chronic adaptations (Caspersen 
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et al 1985, Bouchard and Shephard, 1994). PA can vary in intensity, duration and frequency and 
it includes; activities of daily living, incidental PA, non-exercise activity thermogenesis (NEAT) 
(Levine, 2008, Trembaly et al. 2010) occupational-related activities (Bouchard and Shephard, 
1994, Sheppard, 1995) as well as active transport (Salli et al. 2004). Accumulating these 
differing forms of PA can benefit overall health (Sheppard, 1995, Warburton et al. 2007). By 
performing frequent and short episodes of PA one can accumulate and progress to meet the 
minimum global recommendations of PA, which are 150 minutes of moderate-to vigorous 
intensity PA over the course of the week (Haskell et al. 2007, Warburton et al. 2007, Tremblay et 
al. 2011, WHO, 2010). 
Table 1. Summary of physical activity intervention studies on menopausal symptoms. 
-
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Villaverde- -Sedentary, healthy -12 month -Self-reported -PA group had improved 
Guitierrrezet postmenopausal intervention HRQOL symptomatology 
et. al (2010) women -Control group and -Menopausal andHRQOL 
-Natural PA group symptomatology -Contra 1 had worsened 
menopause -PA was at 50-80% symptomatology 
->70% had of max HR andHRQOL 
BMI>25 2x/week 
Elavsky and -Low PA or -4 month -Perceived QOL, -Improvements in 
McAuley sedentary White intervention satisfaction of life, menopausal symptoms 
(2007) women -Control, Yoga and depression, were observed across all 
->80% of women walking groups menopausal groups, greatest 
were transitioning -Yoga, 2x/week for symptoms, body fat improvement in the 
through menopause 90-mins focused on (DEXA), V02 walking group 
or postmenopausal strength, flexibility, peak, PA 
-Natural balance and 
menopause, no meditation 
HRT -Walking, 3x/week 
for 1-hr was at 50-
75%ofHHR 
BM! - Body mass index, DEXA - Dual-energy x-ray absorptiometry, HHR - Heart rate reserve, 
HRT - Hormone replacement therapy, HRQOL - Health-related quality of life, QOL - Quality of 
life. 
Several researchers have examined the effects of PA and its influence on menopausal 
symptoms. Villaverde-Gutierrezet et al. (2006) conducted an exercise intervention study with 
sedentary postmenopausal women; the women were randomly assigned to either the experimental 
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or the control group. The majority of the study participants were overweight or obese, body mass 
index (BMI) of25-30 and 30< respectively, but asymptomatic of disease. The exercise sessions 
incorporated aerobic conditioning and muscular strength training while maintaining the intensity 
of the exercises between 50-85% of age-predicted maximum heart rate (HR max). It also 
included range of motion movements for the major joints (stretching) and relaxation techniques. 
Initially the exercise duration was 3 0 minutes and progressed to 60 minutes by the end of the 
intervention. The PA sessions were led by a physiotherapist and lighting, temperature and music 
were used to set a relaxing environment for the participants. The self-reported health-related 
quality of life (HRQOL) measurement tool was employed to examine self-reported physical, 
psychological and social dimensions of functioning and well-being, social support, sexual decline 
and problems in the preceding week. Given the high adherence of the participants at 90%, the 
authors reported that a 12 month exercise program consisting of two sessions a week can improve 
the menopausal symptoms and HRQOL of menopausal women. 
Another investigation by Elavsky and McAuley (2007) evaluated the effect of moderate 
aerobic exercise and Hatha style yoga for menopausal symptoms. Participants in the study were 
grouped in one of the following three groups; aerobic (walking), yoga or control (no intervention) 
group. Baseline measurements of menopausal symptoms, PA levels via the Aerobics Center 
Longitudinal Study Physical Activity Survey, maximal aerobic power measured throu~ direct 
gas analysis, body composition via dual energy X-ray absorptiometry, depression, quality of life 
and satisfaction levels. The variables were all measured again following the 4 month 
intervention. The walking intervention consisted of 60 minute sessions three times a week, 
working at 50% of heart rate reserve (HRR) progressing to 75% ofHHR by the end of the four 
months. Concurrently, the yoga group met twice a week and each 90 minute session focused on 
developing musculoskeletal fitness, flexibility and balance, as well as concentration and 
meditation. Both intervention groups accumulated 180 minutes of structured PA per week and 
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were encouraged to incorporate PA outside of the sessions and in their daily lives. The authors 
reported that walking had the greatest effect on attenuating menopausal symptoms, while yoga 
had a lesser overall effect but benefitted the participants more in the sexual domain. 
2.3 MENOPAUSAL TRANSITION AND DISEASE RISK 
A common physiological change during the menopausal transition is a gain in centralized 
adiposity also known as abdominal obesity, visceral obesity and central obesity. Alterations in 
the body's fat distribution from the more traditional gynoid (lower body fat storage) to android 
(upper body storage) is a notable feature (Price et al. 1998). However, it is unclear if fat 
deposition in the intra-abdominal area is a consequence of menopause alone or due to the lifestyle 
habits associated with aging. 
It has been reported that fasting insulin levels are elevated and the risk of impaired 
glucose tolerance is greater when transitioning through menopause (Soler et al. 1989). Since 
estrogen has been shown to have significant effects on carbohydrate and lipid metabolism (Zarins 
et al. 2010), with the lower levels of estrogen during the menopausal transition, carbohydrates are 
more readily metabolized while lipids are stored and spared, contributing to the decrease in fat 
oxidation and greater fat accumulation (Zamboni et al. 1992). The menopausal transition has 
been speculated to predispose women to comorbidities that are obesity-related thereby increasing 
the risk of cardiometabolic diseases (Carr, 2003; Sowers et al. 1995; Barrett-Connor 1993; Price 
et al. 1998). This relationship was established after adjusting for age, BMI, household income 
and physical inactivity (Park et al. 2003). Cross-sectional studies have concluded that decreased 
basal lipolysis and increased lipoprotein lipase (LPL) activity in adipocytes from pre to post 
menopause may be a contributing factor predisposing women to gain fat mass (Ferrara et al. 
2001 ). LPL is an enzyme responsible for hydrolysis of the triacylglycerol found in the blood and 
its uptake and storage of free fatty-acids (FF A) into adipocytes and other metabolically active 
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tissue (Pedersen et al. 2004, Mead et al. 2002). LPL found in adipocytes results in the storage of 
FFA and LPL found in muscle results in the oxidation ofFFA (Ellis et al. 1994). 
Adipose tissue contains two forms of estrogen receptors; estrogen receptor-a and the 
recently discovered estrogen receptor-~ (Pedersen et al. 2004), which allows estrogen to bind to 
the adipocyte and influence processes within. This implies that estrogen plays a role in the 
regulation of the LPL gene expression (Mead et al. 2002). The study by Pedersen et al. (2004) 
demonstrated that estrogen attenuates the lipolytic response in subcutaneous adipocytes through 
up-regulation of the number of antilipolytic 2A-adrenergic receptor. This gene expression 
regulation differs between lower versus upper body, and this difference has been observed to 
change from pre to post menopause (Price et al. 1998). As a result, the lack of estrogen in 
postmenopausal women augments fat accumulation and suppresses LPL gene expression in 
specific areas of the body, contributing to the android fat distribution seen during the 
postmenopausal term. Estrogen now is known to influence substrate metabolism and more 
specifically FOR, however, the menopausal process also involves alterations in many other sex 
hormones such as testosterone, progesterone, etc. which will be discussed in further detail. 
2.4 FAT OXIDATION RATE 
Fat oxidation refers to the metabolic process in which FF As are metabolized to synthesize 
energy for use at rest or during PA. The plasma triglycerides provide a minimum of 50% of the 
FF A source and the remainder is provided by hydrolyzed intramuscular triglycerides (Stefanick 
and Wood, 1994). The proportion of fat to carbohydrate oxidation differs at varying PA 
intensities (Christensen and Hansen, 1939). FF As are the primary source of energy at rest and 
during prolonged sessions of light to moderate intensity PA (below 50% of maximum aerobic 
power) (Stefanick and Wood, 1994), and as the intensity of the PA increases, carbohydrate 
contribution increases and concurrently, fat oxidation decreases (Jeukendrup and Achten, 2001). 
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Substrate oxidation can be estimated by the use of the respiratory exchange ratio (RER), which 
ranges from 0.7 to 1.0 in value, with 100% fat oxidation occurring at 0.7 and 100% carbohydrate 
oxidation occurring at 1.0 of the range (Lusk, 1928). 
The standard method for measuring substrate metabolism is human is through indirect 
calorimetry. This is performed though measuring oxygen consumption (V02) and carbon dioxide 
(VC02) production that provides information on the substrate type and rate of utilization in an 
organism (Lusk, 1976). By measuring V02 and VC02, RER absolute FOR can be calculated. 
Indirect calorimetry is non-invasive compared to other methods such as the use of radioisotopes, 
blood extractions and muscle biopsies and therefore more widely used. Different protocols have 
been designed to measure FOR during exercise, most of them being conducted on a cycle 
ergometer, only calculating FOR at specific intensities while others have created protocols that 
are incremental and measure FOR at multiple sub-maximal exercise intensities. When measuring 
FOR in an incremental to maximum effort protocol it is important to have reasonably short work 
periods (2- 4 minutes) with gradually increasing exercise intensities, allowing both for steady 
state gas exchange to occur but also for more data collection and therefore more FOR calculations 
across a wide range of intensities before the participants becomes exhausted. The FOR at each 
workload and its associated exercise intensity expressed as a percentage of maximal or peak 
oxygen consumption (V02 max or V02 peak) is fitted to a polynomial curve, FOR along they-
axis and% V02 max or V02 peak along the x-axis. This curve will provide information on the 
FOR throughout the exercise, FORmax and the % V02 max or V02 peak that elicited the FORmax, 
referred to as FATmax. Knowledge of the FORmax and FATmax or the range of intensities one 
can oxidize the most FF A have importance in both health-related fitness and performance-related 
fitness (Jeukendrup and Achten, 2001 ). 
Researchers have examined FOR at rest and during varying sub-maximal intensities. 
They have also investigated the differences between sexes, age groups and physical fitness levels. 
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The modality that an individual uses to exercise also influences substrate utilization for the same 
relative intensity in both fed and fasted states (Achten et al. 2003). Researchers examined the 
FOR using the treadmill and compared the FOR using the cycle ergometer (Achten et al. 2003 ). 
They concluded that fat utilization is higher on the treadmill over a wide range of the same 
relative intensities. Also, FORmax attained was greater on the treadmill but occurred at the same 
FA Tmax as on the cycle. A rational for the higher FOR at the different intensities on the 
treadmill is due to the greater muscle mass recruitment during treadmill activities and therefore a 
greater release of catecholamines. Catecholamines are activators of lipid mobilization and thus 
promote fat oxidation during exercise; and the release of catecholamines are relative to the 
muscle mass recruitment (Davies et al. 1974), explaining the greater FOR on the treadmill than 
for cycling exercise. 
Another study, in which the two modalities were compared, reported that the intensity 
that elicited FORmax was higher while running than cycling (Cheneviere et al. 2010). Maximum 
fat oxidation occurred at 57.2% of V02 max on the treadmill and at 44.2% ofV02 max on the 
cycle ergometer (Cheneviere et al. 2010). Participants had to work at a higher intensity on the 
treadmill in order to reach their FORmax· The researcher also concluded that FOR only differed 
between the two modalities when the intensity of the exercise exceeded 70% ofV02 max 
(Cheneviere et al. 2010) and attributed this difference to the greater muscle recruitment during 
treadmill running versus cycling. The different outcomes from these two studies could be 
attributed to the different testing protocols that were used on the treadmill, while Achten et al. 
(2003) used a walking protocol, Cheneviere et al. (2010) used a running protocol. Overall, both 
studies concluded that FOR are greater on the treadmill and fat utilization is higher across all 
workloads on the treadmill in comparison to the cycle ergometer. 
Other variables known to alter fat oxidation are sex, age and maturation, and aerobic 
fitness level. Researchers have shown that women utilize more FF A in comparison to men at any 
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given sub-maximal intensity (D'eon and Braun, 2002). This discrepancy is attributed to the 
higher levels of estrogen and progesterone which are innate to women (D'eon and Braun, 2002). 
Both men and women undergo decreased efficiency of fat utilization at rest as they age, 
regardless of the increase in fat mass (Rising et al. 1996). Furthermore, during exercise older 
individuals oxidize less fat at the same absolute and relative intensities in comparison to young 
adults (Sial et al. 1996). This change in lipid oxidation with age has been related to the decrease 
in skeletal muscle metabolism and not to FF A availability (Sial et al. 1996). Endurance training 
improved lipid oxidative capacities in older adults (Johnson et al. 2010, Zarins et al. 2010) similar 
to levels observed in untrained young adults. 
As a result of endurance training skeletal muscle mitochondrial content increases, which 
in tum results in a greater muscle respiratory capacity (Sial et al. 1998). Efficiency in fat 
utilization through aerobic training has also been documented in young adults (Friedlander et al. 
1998, Sidossis et al. 1998). Similar adaptations occur as in the older adults. Strength training 
also has its effects on improving fat utilization during rest and over a 24-hour period (Treuth et al. 
1995). Factors such as sex, age and fitness level or exercise training have been documented to 
alter the rate at which FFA are utilized at rest and at varying sub-maximal exercise intensities. 
Table 2. summarizes the FOR studies that were discussed above. 
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Table 2. Summary of studies in which the different factors that influence fat oxidation rate were 
examined. 
~~---~ Achten et -I2 healthy, -Cycle, starting stage at 95W, increase -FOR is higher on the treadmill versus 
al. (2003) moderately by 35W every 3-mins until exhaustion cycle over a wide range of the same 
trained men 
-Treadmill, 7 .5km•h"1 at I% incline relative intensities 
-Mean age 2I yrs and incline was increased by 2% every -FORmax attained was greater on the 
-All individuals 3-mins until and RER of I .O was treadmill but occurred at the same 
went through attained relative intensity as on the cycle 
both protocols -FORmax was attained at 59.2% of 
V02 max on the treadmill and at 
62.Io/o ofV02 max on the cycle 
ergo meter 
Cheneviere -13 healthy and -Cycle, began at 40W and increased by - FORmax and FOR from 70-85% of 
et al. (2010) moderately 20W every 3-mins until RER of I .O V02 max were higher for running 
trained men and was attained than cycling 
women -Treadmill, began at 3km•h"1 at I% -FORmax was attained at 57.2% of 
-Mean age 29 yrs incline, speed was increased by Ikm•h- max V02 on the treadmill and at 
-All individuals 1 every 3-mins until a RER of I.O was 44.2% of max V02 on the cycle 
went through attained ergo meter 
both _Q!Otocols 
Sial et al. -6 elderly, mean -Cycle ergomter was used to measure -Mean FOR was 25-35% lower in the 
(1996) age 73 yrs and 6 substrate utilization at 56% of V02 elderly group than in the young 
young mean age max, younger group was measures at adults at both the same absolute and 
26 yrs, matched the same relative and absolute relative intensities 
for gender and intensities -FOR is decreased and carbohydrate 
lean body mass oxidation is increased during 
moderate intensity exercise in elderly 
men and women 
Zarins et al. - I 0 healthy, - I -hr of supervised moderate-intensity -There was a decreased carbohydrate 
(2010) nonsmoking, aerobic exercise 5 days/wk for I 2 and increased lipid oxidation rates at 
postmenopausal weeks ( 4 sessions on the cycle and I the same absolute, but not relative 
women treadmill) exercise intensity 
-Mean age 55 yrs -Training was at 50-65% of peak HR 
Friedlander -8 healthy, -5 days a week for I -hr each day on the -FOR increases after endurance 
et al. (1998) nonsmoking, cycle ergometer. training at the same relative (I I 7%) 
sedentary female -Aerobic training intensity was or absolute (58%) intensity 
between the ages gradually increased from 50% to 75% 
ofI8-35yr ofV02£eak 
Treuth et al. -I3 healthy -Whole body strength training sessions -9. I% increase in resting energy 
(1995) women occurred 3days/wk for I -hr expenditure 
-Mean age 67 yrs -2 sets of 12 reps for each exercise -93 %increase in fat oxidation and 
84% decrease in carbohydrate 
oxidation 
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2.5 FAT OXIDATION RATE AND ETHNICITY: 
Until recently, the FOR in different ethnic groups had received minimal attention in the 
literature. Hall et al. (2010) studied the FOR of South Asian men, an ethnic population that is at 
an elevated risk for developing abdominal obesity and metabolic syndrome. Hall compared the 
South Asian men with BMI-matched European men. Participants were not matched for physical 
fitness levels, but habitual PA levels were measured through the self-report using International 
Physical Activity Questionnaire, and daily food intake was also measured through a food diary. 
PA and food intake were compared between the two groups and no significant differences were 
observed. The authors concluded that the South Asian men had a reduced capacity for fat 
oxidation during sub-maximal exercise in comparison to the European men, after correcting for 
age, BMI and fat mass. The study findings suggest that there may be ethnic differences in FOR 
despite not controlling for physical fitness level. 
Ethnic differences have also been detected and documented in females. Ethnic disparities 
in resting metabolic rate (RMR) and FOR at rest and during exercise (Santa-Clara et al. 2006; 
Rickner et al. 2001) have also been documented between both premenopausal and 
postmenopausal African-American and White women. These studies collectively suggest that the 
lower RMR and FOR at rest and during exercise are linked to the weight gain observed with age 
not necessarily due to the menopausal transition, in African-American females. Anthropometric 
variables and physical activity levels were not matched in these studies between the groups, 
although differences in RMR and FOR were detected between ethnic groups, all confounding 
variables were not controlled for. 
Decreased FOR at rest and during PA may have important clinical implications and can 
influence one's ability to manage weight. Furthermore, significant increases in abdominal 
obesity and overall weight gain have been observed in certain ethnic populations as a function of 
age. In a population-based study, Janghorbani et al (2007) looked at overweight and obesity rates 
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in Iranian adults. They found that 36% of the women between ages 55-64 were overweight and 
31.1 % were obese class 1 using the World Health Organization (WHO) BMI cut-off points; 
underweight <18.5, normal weight 18.5-24.9, overweight 25.0-29.9, obese class I 30.0-34.9, 
obese class II 35.0-39.9 and obese class III >40.0 (WHO, 2000). In the same age group 73.3% 
were categorized as being abdominally obese, having a waist circumference (WC) of 88 cm or 
greater. The Iranian community is a group in which the majority of women above 55 years of age 
are abdominally obese, overweight, or obese therefore possessing physiological characteristics 
that will increase their risk for developing chronic metabolic and cardiovascular conditions (Carr, 
2003). 
2.6 MENOPAUSAL TRANSITION, HORMONAL CHANGES AND THEIR SUSPECTED IMPACT ON FAT 
OXIDATION 
As mentioned earlier, perimenopause is the term used when menstrual irregularities first 
begin and this phase of the menstrual transition is broken up into early and late perimenopause. 
The time frame for each of these periods is individualized to each woman. Menopause is referred 
to the last menstrual cycle the woman has, this is not established until 12 months post when they 
fulfill the criteria. The time from the last menstrual cycle and onward is referred to as post 
menopause, where no further cycles occur. During each of these phases of menopause FSH, 
estrogen, progesterone and testosterone levels shift which are discussed in detail later in the 
current paper. 
The underlying physiological process of the menopausal transition is linked to the 
hormonal alterations. As mentioned before the hormonal changes that occur are that FSH levels 
increase and estrogen, progesterone and testosterone levels drop and these collective changes are 
speculated to influence disease risk as women age (Glendy et al. 1937, Barrett-Connor et al. 1991, 
Brezinika and Padmos, 1994, Carr, 2003 ). Differences in hormone levels have been observed 
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within ethnic groups when researchers examined FOR in White and African-American women 
and discovered that hormonal variations among these women may be used to explain the diverse 
FOR premenopause. More specifically estrogen and genetic disparities have been stipulated as 
the contributing factor in determining the differences between these groups (Santa-Clara et al. 
2006; Hickner et al. 2001 ). In the postmenopausal period, estrogen discrepancies among 
ethnicities persist (Setaiwan et al. 2006) and are assumed to continue to have an influence on 
FOR. Randolph et al. (2004) demonstrated that estrogen and FSH levels varied by ethnicity when 
measured longitudinally over the course of the menopausal transition, indicative· of ethnic specific 
variations in the pituitary-ovarian relationship. 
Estrogen and FSH levels also differed between age independent of menopausal status and 
the influence ofBMI varied by menopausal status (Randolph et al.2004). In the premenopausal 
and early perimenopausal phases BMI had a negative effect on estrogen in comparison with the 
transition from late perimenopause to post menopause where BMI had a positive effect on 
estrogen levels (Randolph et al.2004). The number of children and the age of first birth have not 
been associated with significant differences in hormone levels, whereas late age at menarche was 
modestly associated with decreased estrogen concentrations post menopause (Setaiwan et al. 
2006). Different variables have shown to effect hormone levels premenopause as well as through 
the menopause transition, which indirectly influence FOR. 
Alterations in the hormonal milieus of women continue to impact their health in the later 
years of life. In brief, in a normal healthy female, estrogen concentrations drastically decrease 
through the menopausal transition and FSH levels increase in response. The biological measure 
of menopause occurs when FSH levels exceed 50 ill/ml (Burger et al. 1995) in addition to having 
no menstrual cycles in the preceding 12 months. These modifications influence the 
concentrations of other metabolism altering sex hormones such as progesterone, testosterone and 
luteinizing hormone (LH); therefore making way to alterations in substrate metabolism by 
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favoring fat storage and influencing woman's overall physiology. When estrogen levels decrease 
dramatically at the onset of the menopausal transition, FSH increase while LH levels stay 
relatively stable, these are the two hormones that assist in follicular maturation and the production 
plus release of estrogen (Soules and Bremner, 1982). The elevated FSH levels are required to 
mature the follicles in the ovaries and prepare them for conception, this no longer occurs during 
the menopausal transition (Soules and Bremner, 1982). FSH levels will increase as estrogen 
levels decrease and inhibin, a regulator of FSH, will also increase in response to decreased levels 
of FSH (Soules and Bremner, 1982, Randolph et al. 2004 ). During the menopausal transition the 
main goal of FSH is to promote estrogen secretion and follicular maturation. The influential 
effect of increased FSH levels during and after ovarian failure and its relation to the FOR is 
unknown. These collective hormonal changes are the start of may other physiological changes 
that occur during the menopausal transition. 
There are different forms of estrogen, each one having its dominance during different 
stages of life and the reproductive cycle. Estradiol is the prominent form and the most 
physiologically active form in the younger years where as estrone is the most prominent form of 
estrogen post menopause. Both forms of estrogen are produced from circulating steroids that are 
released by the ovaries and by the adrenal glands. Steroids converted in the ovaries produce 
estradiol and steroids converted in the adipocytes produce estrone (Kalyani et al. 2009) and the 
transcription of estrone increases with age (Price et al. 1998). Estrogen, regardless of its form, is 
still the main factor in determining women's ability to oxidize fat (D'eon et al 2002), but with 
reduced levels its role in fat oxidation is diminished. Estrogen receptors have been found on 
adipocytes which indicate that estrogen plays a role in lipid metabolism (Pedersen et al. 2004 ). In 
addition to estrogen receptors, progesterone and androgen receptors have also been found on 
adipocytes (Mayes and Watson, 2004) which lead to the idea that these hormones may also have 
an effect on lipid metabolism. Figure 2 summarizes how different levels of estrogen and 
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progesterone affect lipid synthesis and metabolism in muscle and adipose tissue using results 
from animal studies. 
Progesterone is also a steroid hormone but its source of production and release is 
different than estrogen; progesterone is released from the corpus luteum, placenta and adrenal 
glands and it is a precursor for the production of testosterone and estrogen (D'eon and Braun, 
2002). Studies observing the effects of progesterone on FOR in both human and animal studies 
have observed mixed results (D'eon and Braun, 2002). Human studies that observed different 
phases of the menstrual cycle when progesterone levels are elevated above estrogen levels (Toth 
et al. 1987, Hackney et al. 1994), it was difficult to ascertain the effect of progesterone 
independent of estrogen on FOR (D'eon and Braun, 2002). In animal studies looking at 
ovariectomized rats, researchers found progesterone behaved similarly to estrogen in suppressing 
carbohydrate utilization and promoting fat oxidation (Kendrick et al. 1987, Kalkhoff, 1982), 
whereas others investigators found that to have a opposing effect to estrogen, FOR was reduced 
(Hatta et al. 1988, Hansen et al. 1996, Campbell and Febbraio, 2001). Once again, Figure 2 
briefly summarizes how estrogen and progesterone influences fat metabolism using an animal 
model. Links between progesterone and testosterone (androgen) levels with lipid metabolism 
have not been established in postmenopausal women. The concurrent decrease in progesterone 
and testosterone levels decrease along with estrogen may have an impact on FOR. 
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Figure 2. 'The effects of estrogen and progesterone on pathways of carbohydrate and fat 
metabolism. Mechanisms shown are derived from an integrated view of data collected in animal 
models.' Modified from D'eon et al. (2002). CPT-1 caratine palmityltransferase 1, TG 
triglycerides, incr increase, deer decrease, E estrogen, P progesterone. 
Low amounts of ovarian estrogen result in greater amounts of inhibin and the up 
regulation ofFSH (Soules and Bremner, 1982, Randolph et al. 2004). FSH and LH are hormones 
that are responsible for the stimulation of the ovaries to release sex hormones (estrogen, 
progesterone, testosterone) and mature the follicles. The influential effect of FSH and LH on sex 
hormone levels after ovarian failure is unclear and its relation to the FOR is unknown. Sex-
hormone binding globulin (SHBG) levels, a protein responsible for the transport of estrogen and 
testosterone, also drop concurrently with sex hormones levels. There is a difference in the 
affinity of SHBG for the different sex hormones; it has a greater affinity for testosterone than for 
estrogen and therefore a greater binding and transport capacity for testosterone and reduced 
capacity for estrogen (Janssen et al. 2008). This selective property of SHBG influences the 
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transport of estrogen by favoring testosterone transport and therefore serves as a marker of 
estrogen bioavailability (Janssen et al. 2008) which also is an indirect measure of androgenicity 
(Kalyani et al. 2009), elevated testosterone levels. Therefore, the effects of testosterone on the 
physiological process within women during the postmenopausal term are enhanced. 
Associations have been made in a longitudinal cohort study, between elevated levels of 
testosterone and suppressed levels of SHBG with overall obesity and abdominal obesity in 
women independent of age, PA and other chronic health conditions (Sutton-Tyrrell et al. 2010). 
In a cross-sectional study, elevated testosterone and low levels of SHBG were found to impair 
fasting glucose in postmenopausal women (Kalyani et al. 2009). In men, testosterone plays an 
important role in substrate metabolism (Saad and Gooren, 2011) and low levels have shown to be 
negatively associated with blood pressure, fasting plasma glucose, triglycerides, body mass index 
and abdominal obesity, as well as demonstrating positive correlations with HDL-cholesterol 
(Marin et al. 1996). Sutton-Tyrrell et al. (2010) suggest that high levels of androgens impair 
insulin action in skeletal muscle and adipose tissue, contributing to reduced whole-body insulin 
sensitivity; a known physiological characteristic of menopause. With the emerging evidence of 
androgen receptors being located on adipocytes the effect of testosterone on FOR in women is not 
well understood and with the increased dominance of testosterone post menopause it is crucial to 
understand its influences. Free testosterone can also be measured in women when SHBG and 
testosterone levels are known and this value is known as a free androgen index (F Al). This is a 
ratio of total testosterone to the concentration or the binding capacity of SHBG (V ankrieken, 
1997). Strong relationships were established between obesity and high free F AI and low SHBG 
in postmenopausal women (Sutton-Tyrrell et al. 2010). Elevated androgen levels are now 
considered as a predictor of obesity in women transitioning through menopause (Sutton-Tyrrell et 
al. 2010). 
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Insulin is a metabolic stabilizing hormone that influences substrate utilization by 
controlling the storage and breakdown of glucose (Saltiel and Kahn, 2001 ). It is known that 
insulin greatly inhibits the breakdown of fat in adipocytes through reducing the activity of 
hormone sensitive lipase (HSL) and increases lipid synthesis (Saltiel and Kahn, 2001, Bjomtorp, 
1996). Insulin resistance trails the development of abdominal obesity (Janssen et al. 2008, Kohrt 
et al. 1993) and in the case of insulin resistance there is an excess of insulin. As mentioned 
before SHBG levels affect estrogen and testosterone activity and now it is being postulated that 
insulin may inhibit SHBG secretion (Svendsen et al. 1993). Janssen et al. (2008) have inferred 
strong associations between incident metabolic syndrome to higher F AI and lower SHBG levels. 
Moreover, insulin does not only control lipid metabolism directly but it influences estrogen and 
testosterone bioavailability through the management of SHBG secretion, which then can effect 
FOR. 
Cortisol is a hormone that fluctuates throughout the day in response to life's everyday 
stressors. Like insulin, cortisol promotes lipid synthesis at the adipocyte, inhibits adipose tissue 
metabolism and affects fat distribution (Bjomtorp, 1996, Bjomtrop, 1997). Researchers suggest 
that cortisol levels increase in response to abdominal obesity (Bjomtorp, 1996) and high cortisol 
levels have been associated with a greater waist to hip ratio and abdominal obesity in 
postmenopausal women (Marin et la. 1992). Paradoxically, cortisol is also linked to increases in 
adipose tissue lipase enzyme expression, which would be expected to increase the capacity for 
lipolysis (Peckett et al. 2011 ). Table 3 summarizes all the hormonal changes that take place 
throughout the menopausal transition. 
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Table 3. Summary of the function and production of hormones and the changes as a result of 
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Estradiol -Produced in adipocyte and adrenal glands i j lipid metabolism 
-More active form 
Estrone -Produced in ovaries ! j lipid metabolism 
-Less active form 
Progesterone -Precursor to estrogen and testosterone production ! j ! unclear 
-Produced in the corpus luteum, placenta and 
adrenal glands 
Testosterone -Produced in the ovaries ! Unknown, high FAI 
linked to obesity 
Follicular -Released from the pituitary i Unknown 
stimulating -Responsible to the stimulation of ovaries to release 
hormone sex hormones 
Luteinizing -Released from the pituitary ~ Unknown 
hormone -Responsible to the stimulation of ovaries to release 
sex hormones 
Sex-hormone -Transports estrogen and testosterone Slight! Unknown, low levels 
binding globulin -Has a greater binding and transport capacity for linked to obesity 
testosterone than for estrogen 
Insulin -Released by the pancreas j as result of j lipid synthesis and 
-Influences substrate utilization by controlling the insulin inhibits lipid 
storage and breakdown of glucose insensitivity metabolism 
Cortisol -Released by the adrenal glands j with an j j ! unclear 
in central fat 
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3.0 RATIONALE, PURPOSE AND HYPOTHESIS 
Although fat oxidation and cardiometabolic disease risk have been studied in various 
ethnic groups, ME women are a group for whom no information has been reported on either FOR 
or the effects of the menopausal transition on disease risk. The purpose of this study was to 
compare resting plus exercise FOR, FORmax, F ATmax, hormone levels, anthropometric 
characteristics, PA levels and cardiometabolic risk factors between postmenopausal ME and W 
women. It was hypothesized that the ME women would exhibit lower FOR at rest and at 
different sub-maximal exercise intensities and have a lower FORmax and FA Tmax as well as, 
lower levels of estrogen and posses higher cardiometabolic risk factors compared to the W 
women. 
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4.0METHODS 
4.1 PARTICIPANTS AND RECRUITMENT 
Participants were recruited through friends, fellow students, advertisement posted 
throughout York University, and networking through cultural community centers. Once the 
recruitment process was completed the participants were grouped based on their ethnic origin ME 
or W, which was determined by their birthplace. Menopausal status was based on the number of 
menstrual cycles the participant reported having in the past 12 months in the pre-screen and 
confirmed by their FSH level, >30 mIU/mL with the blood draw. Participants were healthy 
females, undiagnosed of any major illness, not on metabolic altering medications or hormone-
replacement therapy, and had not undergone surgically induced-menopause. In order to attain 
power of 0.05 for a two-tailed alpha with an effect size of 0.8, 12 participants were recruited for 
each group. 
4.2 PRE-SCREENING 
Before the initiation of the exercise protocols, the participants were taken through an 
extensive pre-screening procedure. Pre-exercise screening took place on the first experimental 
day. They completed the Physical Activity Readiness Questionnaire for Everyone+ (PAR-Q+) 
(Warburton et al. 2011) (Appendix A) and an Informed Consent document (Appendix B). The 
P AR-Q+ was used to clear the participants for exercise and to confirm the absence of any 
metabolic conditions that may hinder the outcome of the research. The participants had no 
contraindications or restrictions to exercise participation based on their responses on the PAR-
Q+. Participants that were not taking medications for diabetes, cholesterol or hormone 
replacement therapy were accepted into the study. In addition to explaining the risks involved in 
taking part in the research, the Informed Consent document outlined the purpose, importance of 
the study and how it will add to the existing body of research and improve clinical practices in 
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weight management and disease prevention. Pre-exercise heart rate (HR) and blood pressure 
(BP) were measured using the BpTRU, electronic blood pressure monitoring device, to ensure 
participants were within an acceptable range before the initiation of the exercise protocols; BP 
<160/90 mmHg and free of comorbidities (Thomas et al. 2011 ). The participants had their blood 
pressures and heart rates measured on both the right and left arms while seated in a relaxed 
position, feet flat on the ground and legs uncrossed. Six measurements were taken consecutively 
and averaged. The average values were obtained and used in the analysis. 
4.3 PARTICIPANT CHARACTERISTICS 
4 .3 .1 Anthropometric Characteristics 
Standardized protocols were used to measure height, weight and waist circumference 
(WC). Height was measured without shoes using a stadiometer (Fitness Precision, Toronto 
Ontario). Body mass was measured using a digital scale (Seca Alpha, Germany) with no shoes 
and light clothing. WC was measured using the National Institute of Health (NIH) protocol; the 
measuring tape was placed on the skin at the level of the iliac crest. Body fat percentage was 
determined through bioelectrical impedance analysis instrument (Tanita Scale, model TBF-612, 
Arlington Heights, Ill). Skinfold measurements were taken using Harpenden fat calipers at 
standard sites; bicep, tricep, subscapula, iliac crest and medial calf, as per the Canadian Physical 
Activity, Fitness and Lifestyle Approach (Gledhill and Jamnik 2003). Markings were made at the 
skinfold sites as well as one centimeter below, first for where the fold was made and the second 
for the placement of the jaws of the fat caliper. BMI was calculated using body mass in 
kilograms divided by height in meters2• BMI, WC along with skinfold sum was used to rate the 
participants' Composite Body Composition Health Risk Score (Gledhill and Jamnik, 2003). 
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4.3.2. Physical Activity 
Participants' PA levels were characterized through the use of omnidirectional Actical 
(Respironics Inc, 2008) accelerometers and the self-reported Healthy Physical Activity 
Participation Questionnaire (HPAPQ) (Gledhill and Jamnik, 2003). Both objective and subjective 
forms of PA assessment tools were used to reduce associated limitations and biases. The 
accelerometers allowed for 15-second epoch analysis of intensity and volume of PA, step counts 
and energy expenditure (EE) (Riddoch et al. 2007), while the questionnaire provided information 
on the frequency and intensity of the activity as well as perceived fitness (Gledhill and Jamnik, 
2003). PA levels with the accelerometers were tracked over a 3-day period consisting of two 
weekdays and one weekend. The accelerometer was worn on a waist belt located over the iliac 
crest. A minimum of 600 minutes of data per day was collected for adequate analysis, 10 waking 
hours out of a 24-hour day (Riddoch et al. 2007). As illustrated in Figure 3. the accelerometers' 
software program provided detailed graphs for each participant where the datum was obtained. 
The graphs provided activity counts, step counts for 15-second epoch periods of time and hourly 
averages of EE. Activity counts are a measure of PA that considers both the intensity and 
frequency of the activity. The three-day averages for each of the measurements were calculated 
and used in the analysis in addition to the raw HP AQ scores. 
- 25 -
Figure 3. Actical accelerometer graph example. 
A) Visual of 2 day collection, black line graph illustrate activity count, blue line graph illustrates 
step counts, green bar graph illustsrates hourly EE without including resting metabolic rate 
calculated through body surace area equation. 
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B) Same as above but hourly EE includes computer calculated resting metabolic rate. 
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4.4 BLOOD AND URINE PROFILE 
Blood samples were drawn from each participant at the beginning of the second session 
while in a fasted state to characterize the blood lipid, sex hormone and glucose levels. The blood 
extractions were performed by a certified phlebotomist. When the blood was obtained from the 
participants, the vials rested for 30 min before being spun in a centrifuge for 15 min. After the 
samples were spun the plasma was transferred to storage vials to be sent out to an external 
laboratory (Canadian Life Labs) for analysis. 
Lipid Panel. HDL-cholesterol, LDL-cholesterol, triglycerides, total cholesterol, were measured 
and the HDL-cholesterol to total cholesterol ratio was calculated to ensure normal blood lipid 
levels for each participant. 
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Hormone Panel. As part of the blood draw, the following hormones were analyzed; estradiol, 
estrone, progesterone, testosterone, SHBG, androgen index which was calculated using the values 
from the testosterone and SHBG, FSH, LH, and insulin. 
Urine Sample. Urine samples were obtained to measure cortisol levels. The urine samples were 
taken on the same morning as the blood draws, while in a fasted state. The sample was collected 
in sterile urine cups and transferred to vials to be sent to an external laboratory (Canadian Life 
Labs) along with the blood samples for analysis. 
4.5 EXERCISE PROTOCOL 
Open circuit spirometry, a form of indirect calorimetry was used during the graded 
exercise test and the fat oxidation protocol. The details of the open circuit spirometry involved, 
the participant inhaling air from the atmosphere and expiring air through a mouth-piece attached 
to a two-way valve (Ewald Koegal Co, San Antonio Texas), connected to a hose and then to a 
120L Tissot gasometer (Warren E Collins LTD. Braintree, Massachusetts), while wearing a nose 
plug. The fractional concentration of expired oxygen (FE02) and carbon dioxide (FEC02), and 
volume of air expired, or minute ventilation (VE), were measured in the final 30 seconds of each 
2 min workload and from that V02 and VC02 was calculated. Oxygen and carbon dioxide 
fractional concentrations of the expired air were analyzed through rapid response gas analyzers 
(Applied Electrochemistry, Model S-3A and CD-3S, Sunnyvale, California). The graded exercise 
test was performed on the first day the participants arrived in the laboratory. The tests were 
conducted by qualified exercise professional (Warburton et al. 2011 ), the first exercise day was 
used to familiarize the participant to walking on a treadmill and to take them through an 
incremental to maximum effort treadmill loading sequence for the determination ofV02 max or 
V02 peak. 
Participants wore electronic heart rate monitors (Polar Electro, Kemple Find/and) during 
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the incremental to maximal test, the protocol for this test had 2-min work stages that increased in 
intensity at every stage, the last 30-seonds of the 2-min stages were when the gas collection took 
place, HR and the rating of perceived exertion (RPE) were also obtained. The participants were 
instructed to remain on the treadmill until they reached volitional fatigue at which point they 
received a 2-minute low-intensity active recovery. Following the recovery period, the 
participants continued the test for another stage, and then were given another 2-minute break after 
completing the workload. This discontinuous portion of the graded exercise test was used to 
ensure that the attainment ofV02 max or V02 peak. The test was terminated when the participant 
was either no longer able to continue or when the criteria for attaining V02 max was reached. 
The attainment ofV02 max was determined by applying the following criteria; a plateau in V02 
with increasing workloads where V02 does not increase more than 1.5 mL of 0 2·kg-1·min-1, a 
respiratory exchange ratio (RER) value greater than 1.15, and no increase in heart rate with an 
increase in workload (Howley et al. 1995; Heyward, 2006). The term V02 peak is being used in 
this study instead ofV02 max because most participants did not exhibit the criteria for attaining 
V02 max, the V02 values that were obtained represented a peak. 
On the second experimental day, the study participants underwent the fat oxidation 
protocol following an 8-10 hour overnight fast. The fat oxidation protocol was a modified 
version of Achten, Venables and Jeukendrup treadmill protocol (2003). The workloads were the 
same duration in length and the increase in intensity at each new stage was consistent, but the 
current protocol was walking in nature, rather than running. At the start of the protocol, 
electronic heart rate monitors were strapped onto the participants around their chest on the skin in 
order to measure heart rate at different workloads in addition to RPE. Resting V02 and fat 
oxidation measurements were obtained with the participant seated in a chair. Expired air was 
collected at rest for 5-6 minutes, a nose plug was used to prevent any air from leaking out from 
the nose and to ensure that all the expired air was collected in the Tissot tanks. Expired gas was 
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collected and analyzed; VE, V02 and VC02 were calculated, similar to the graded exercise test 
and then used in the formula to calculate FOR. The protocol began at 1.5-1.8 mph and 1 % 
incline; depending on the comfort and height of the participant. Speed increased by 0.2 mph 
every 3 minutes until the participant was at a brisk walking pace, 3.4-3.6 mp~. Once the 
maximum walking speed was attained, the incline increased by 2% every 3 minutes thereafter, 
until an RER of 1.0 or greater was obtained. The last 60-30 (in the earlier workloads a longer gas 
sample was obtained) seconds of the workload were used to collect the expired gases for the 
calculation of FOR. At the end of each workload both HR and the participants' RPE score were 
obtained and were used to gage the participants' work intensity. The third day was used to 
perform a second trial of the fat oxidation protocol, the same starting speed and loading sequence 
were used, duplication of the first trial was attempted. The FORmax values of the two trials were 
used in the analysis. 
Since walking is the more common form of movement and transportation in daily human 
life, the use of a treadmill/walking protocol was used in this study to assess FOR over a range of 
sub-maximal intensities. Walking is a movement familiar to all people and is a representative of 
daily movements in comparison to cycling. The use of a walking protocol makes this study 
unique in that walking is a weight-bearing activity which incorporates greater muscle recruitment 
resulting in a greater demand for energy. While, most studies have employed a cycle ergometer 
protocol as their method for measuring FOR. The study schematic is summarized in Figure 4. 
Figure 4. Participant 3-day data collection schema. 
•PAR-Q+ and consent form 
•Anthropometric 
measurements 
•Accommodate subjects to 
the treadmill and 
breathing apparatus 
•Graded maximal exercise 
test 
•Blood and urine 
samples extracted 
•First trial of fat 
oxidation protocol 
•Second trial of fat 
oxidation protocol 
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4.6 CALCULATION OF FAT OXIDATION RATE 
Frayn's (1983) equation for the calculation of FOR was employed to measure substrate 
oxidation at each workload using indirect calorimetry. Urinary nitrogen excretion rate was 
assumed to be negligible for the purpose of the calculations. The equation is as follows: 
FOR was expressed relative to fat-free mass (FFM) and by body mass for each participant at each 
workload. The FOR relative to FFM were used to create the FOR curves for each participant and 
the analysis of resting and FORmax· 
4. 7 ETHICS APPROVAL 
Ethics approval was obtained from the Human Participants Review Sub-Committees of 
York University (Toronto, Ont.) before the initiation of the study. All the women provided 
written Informed Consent to their voluntary participation in the study. 
4.8 STATISTICAL ANALYSIS 
The study participant characteristics were expressed as means and standard deviations 
(X±SD). An independent t-test was used to determine differences between the ME and the W for 
the anthropometrics, menstrual characteristics, resting BP and HR, PA levels, blood lipid panel, 
blood hormone panel, glucose, resting V02, and V02 peak. A paired t-test was performed on the 
two trials of the fat oxidation trials to determine any differences between the two occasions. 
Regression analysis was performed on the all the hormones and other measured variables against 
WC and FOR for each group. Statistical analysis was conducted using a standard statistical 
software program, SPPS 20.0 (2012). 
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5.0RESULTS 
A total of23 participants were recruited for this study, 12 in the Wand 11 in the ME 
group. All were cleared during the pre-screening to participate in the study. Anthropometric, 
menstrual and age measures are shown in Table 4. Significant differences between the groups 
where observed at age of study participation the ME were younger (p= 0.004), ME observed their 
first period at an earlier age (p= 0.023) and had their last menstrual cycle early in life (p= 0.031). 
Menstrual age, time since first and last cycle was shorter in the ME group (p= 0.007), ME had a 
higher body mass (p= 0.027), a higher BMI (p= 0.32) and a larger WC (p= 0.005). 
Table 4. Age, menstrual characteristics and body composition of the White and Middle Eastern 
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Age (yrs) 57.1± 3.3 52.6 ± 2.8 0.004* 
Age of First Cycle (yrs) 12.2 ± 8.2 13.3 ± 1.1 0.023* 
Age of Last Cycle (yrs) 51.1±2.6 46.5 ± 5.7 0.031 * 
Menstrual Age (yrs) 39.0 ± 2.2 32.2 ± 5.6 0.007* 
Height (cm) 161.5 ± 4.6 162.2 ± 5.9 0.738 
Body mass (kg) 71.0± 12.1 84.0 ± 16.7 0.027* 
BMI 27.0 ± 3.8 31.8 ± 5.9 0.032* 
NIH Waist Circumference (cm) 90. 9 ± 11.0 106.1±11.2 0.005* 
Sum of 5 Skinfolds (mm) 107.5 ± 35.6 136.1±49.3 0.146 
Tanita Foot Scale Body Fat(%) 37.0 ± 5.4 41.7 ± 6.4 0.085 
*sign.ificant difference between groups 
Table 5 contains a summary of the cardiometabolic measures for both groups. 
Differences between the groups were only detected in the relative V02 peak measurement (p= 
0.003) which was higher in the W group. Accelerometer and self- reported measurements; step 
counts, EE, activity counts and scores on the HP APQ are summarized in Table 6. The objective 
measurements from the Actical accelerometers did not show significant differences between the 
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groups. The self-reported HP APQ demonstrated that the W group had a higher perception of 
their fitness and PA level (p= 0.017). 
Table 5. Cardiometabolic characteristics for the White and Middle Eastern study participants with 
t-test and p-values for differences between groups 
1
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Resting Blood Pressure Left Arm 
109/72 ± 12/11 114/72 ± 1319 0.427 I 0.854 (mmHg) 
Resting Blood Pressure Right Arm 
113172 ± 1619 113/74 ± 14/10 0.901I0.747 (mmHg) 
Resting Heart Rate (bpm) 67 ± 7.2 72± 12 0.199 
Resting V02 Relative (mL02·min- 3.63 ± 1.05 3.90 ± 0.83 0.527 1
•kg of body mass) 
Resting V02 Absolute (L02·min-1) 257.0 ± 0.085 0.309 ± 0.047 0.097 
V02 peak Relative 28.16 ± 5.09 21.45 ± 3.79 0.003* (mL02·min-1•kg of body mass) 
V02 peak Absolute (L02·min-1) 1978.0 ± 0.344 1. 776 ± 0.343 0.195 
Peak Heart Rate (bpm) 164± 9 158 ± 10 0.131 
*significant difference between groups. 
Table 6. Physical activity measurement for the White and Middle Eastern study participants with 
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Step Count (steps) 10,205 ± 5 387 7,823 ± 3 304 0.220 
Total Energy Count (kcal) 725.5 ± 571.4) 762.0 ± 578.0 0.880 
Activity Count (intensity) 172 135 ± 101 216 130 038 ± 68 103 0.260 
HPAPQ 9.3 ± 2.1 6.2± 3.5 0.017* 
*significant difference between groups. 
The FOR was calculated using the V02 and VC02 measured at each work load. The 
calculated FOR and the corresponding% ofV02 peak were used to create the curves on the 
GraphPad PRISIM 5 computer software. Following standard procedures, measured resting values 
were not included in the creation of the curves, because the calculated resting FOR were negative 
values (Chui, 2011). A negative FOR is not biological possible, this has occurred as a result of 
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hyperventilation during the resting gas collection. FOR and % V02 peak for each workload were 
used to graph the curves, FOR was graphed along the y-axis and% ofV02 peak along the x-axis. 
Participants' FORmax values and FATmax for both trials of the protocol are shown in Table 7. A 
second trial of the fat oxidation protocol for one participant in the ME group was not obtained due 
to inability to complete the full protocol and therefore the final number of participants used in the 
analysis was 22. Figure 5. depicts the FOR.max and %V02 peak for trials 1and2. A mean FORmax 
of 7.89 (g•min-1•kg of fat free mass) was attained for trial 1 and 8.53(g•min-1•kg of fat free mass) 
for trial 2 (not significantly different, NS). FATmax was attained at 46.2 % V02 peak for trial 1 
and at 47.3 %V02 peak for trial 2 (NS). The strength of the relationship between the two trials 
for FORmax is R2=0.829 {p<0.00) and %V02 peak is R2=0.333 (p=0.13). No differences were 
detected between trials, when comparing FORmax of ME and W women. Since no differences 
were detected from one trial to the next, the 2 trials were then compiled and fitted to a single 
curve for each participant to allow for more data points to create a best-fit polynomial curve. 
When the data were compiled from both trials, the curves were fitted to a third order 
polynomial. The more commonly used second order polynomial resulted in lower R2 values for 
the ME women. The R2 represents the fit of the curve to the actual data points. Most curves from 
the ME women had a R2 value of less than 0.5, indicating that the points did not fit well to a 
second order polynomial curve. The R2 0.5 is the accepted cut-off point that has been used in 
previous studies measuring FOR and fitting them to curves (Chui, 2011 ). When the data points 
were fit to a third order polynomial for the ME the R2 values were significantly higher (p=0.048). 
There were no significant differences between the second and third order polynomials R2 values 
for the W women (p=0.683). The associated tables and statistics are found in Appendix F. 
The FOR.max and F ATmax as well as t-test scores for both groups are shown in Table 8. 
To maintain consistency with previous researchers who have studied FOR, only curves that had a 
R2 value greater than 0.5 were included in the analysis (Chui, 2011). No significant differences 
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were detected between groups for FORmax or FAT max. FORmax, FAT max and exercise 
intensities that elicited FOR at 5%, 10%, and 20% below the FORmax were determined for each 
participant's curve. These specific points were then averaged and plotted against the average 
FOR to provide a range of exercise intensities that elicit the highest FOR for each group. Curves 
were then compiled for each group and plotted to provide average: FORmax, FOR at 5%, 10%, and 
20% of FORmax and the associated exercise intensities, as well as FA Tmax, along with the 
variance bars for both groups (Figure 6). 
Table 7. Trials 1 and 2 ofFORmax and FATmax with paired t-test p-values for differences 
between the trials. 
FORmax (g•min-1•kg of fat free mass) 7.89 ± 3.04 8.53 ± 3.12 
FA Tmax (% of V02 peak) 46.2 ± 11.6 47.3 ± 11.3 
Figure 5. Reproducibility ofFORmax and FATmax from trial 1 to trial 2 
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Table 8. Average fat oxidation characteristics for the White and Middle Eastern women and t-test 
1 £ d'fD ces betw 
Average FORmax (g•min-1•kg of fat free 8.17±(3.24) 9.0 (3.22) 0.587 
mass) 
Average FATmax (% V02 peak) 49.3(8.41) 44.8 (12.56) 0.367 
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Figure 6. Fat oxidation rates for White and Middle Eastern participants at FORmax and at +95%, 
-95%, -90%, -80% ofFORmax with its associated %V02 peak. 
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The hormonal and blood profiles are shown in Table 9 along with select laboratory 
normative data (Canadian Life Labs) for postmenopausal women. A complete blood sample 
was not available for 1 participant in the ME group. For some variables there is a n=l 1 and the 
remainder have a n=lO, this has been indicated in the Table. Significant differences were not 
detected between the two groups, indicating that there are no hormonal variations between these 
two ethnicities. Some of the laboratory tests had low sensitivity, therefore accurate values were 
not provided for estrone and progesterone, instead a range was provided. This inaccuracy of the 
hormone values may have masked the ability to detect any significant disparity. 
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Table 9. Hormone, blood lipid results of the White and Middle Eastern participants with t-test and 
p-values for differences between groups, as well as laboratory normative values for 
ostmeno ausal women. 
Estradiol (pmol/L) 84.93 ± 31.38 71.27 ± 4.55 0.163 < 120 pmollL 
(n=ll) 
Estrone (pmol/L) 138.25 ± 65.45 155.00 ± 52.74 0.522 52-379 pmol/L 
(n=lO) 
Progesterone (nmol/L) 1.08 ± 0.29 1.36 ± 0.68(n=l1) 0.224 < 3 nmol/L 
Testosterone (nmol/L) 1.33 ± 0.60 1.12 ± 0.63 (n=lO) 0.421 NIA 
Follicular Stimulating 85.0 ± 26.9 68.6 ± 28.9 (n=l 0) 0.184 > 35 IUIL 
Hormone (IU/L) 
Luteinizing hormone 38.8 ± 12.3 33.4 ± 11.2 (n=l 0) 0.304 40-105 IUIL 
(IUIL) 
Sex Hormone-binding 45.04 ± 15.96 43.84 ± 21.91 0.883 18.0-144.0 nmol/L 
Globulin (nmol/L) (n=l) 
Androgen Index 0.213 ± 0.131 0.146 ± 0.118 0.225 NIA 
(n=lO) 
Cortisol (nmol/L) 715.58 ± 1436.90 190.09 ± 100.50 0.232 NIA 
(n=l l) 
Insulin (pmol/L) 46.08 ± 20.81 64.90 ± 50.98 0.275 NIA 
(n=l 1) 
Glucose, fasting 5.33 ± 0.49 5.39 ± 0.80 (n=lO) 0.840 3.6-6.0 nmol/L 
(nmollL) 
Total Cholesterol 5.53 ± 1.32 5.08 ± 1.21 (n=lO) 0.425 NIA 
(nmollL) 
LDL (nmol/L) 3.42±1.15 3.12 ± 0.78 (n=lO) 0.502 < 2.0 nmol/L 
HDL (nmollL) 1.57 ± 0.35 1.28 ± 0.57 (n=lO) 0.166 NIA 
CH/LDL ratio 3.69± 1.16 3.98 ± 1.03 (n=lO) 0.548 NIA 
Triglyceride (nmollL) 1.21±0.61 1.33 ± 0.64 (n=lO) 0.657 < 1. 70 nmollL 
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6.0 DISCUSSION 
The purpose of this study was to compare FOR at rest and during incremental exercise, 
FORmax, FA Tmax, hormone levels, anthropometric characteristics, PA levels and cardiometabolic 
risk factors between postmenopausal ME and W women. It was hypothesized that the ME 
women would exhibit lower FOR at rest and at different sub-maximal exercise intensities and 
therefore have a lower FORmax and FAT max as well as, have lower levels of estrogen and posses 
higher cardiometabolic risk factors compared to the W women. In contrast to the hypothesis, no 
between group differences were observed between resting FOR, FOR during incremental 
exercise, FORmax, FAT max, hormone levels, height, body fat%, skinfold measurements, PA 
levels, resting BP, resting HR, resting V02, exercise HR max, fasting blood glucose and fasting 
blood lipid profile. If anything, FOR tended to be higher in the ME group compared to the W 
group (see Figure 6). However, small differences were observed in BMI, body mass, WC, age at 
first and last menstrual cycle, age at study participation and V02 peak. 
6.1 ANTHROPOMETRICS AND PHYSICAL ACTIVITY 
The ME women were found to be significantly younger than the W women, although all 
participants in both groups were postmenopausal. The participants in the groups were essentially 
a convince sample of postmenopausal women which resulted in this unplanned difference. The 
ME women had their first menstrual cycle at a later age and experienced their last menstrual cycle 
at an earlier age compared to the W women. These findings coincide with the epidemiological 
study by Memon et al. (2002) in which they examined reproductive, hormonal characteristics and 
incidence of thyroid cancer in ME women. The authors reported that ME women experienced 
their first and last menstrual cycle at an average age of 13.2 years and 45.8 years respectively. 
These two values provide information on menstrual age which is the time between first and last 
menstrual cycle. According to the Memon et al. (2002) study their calculated menstrual age is 
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32.6 years, which is very close to the findings of this current study of 32.2 years. Little has been 
reported on menstrual age in the literature. This variable quantifies the length of reproductive 
hormone exposure in women, since estrogen, progesterone and testosterone have all been linked 
to influencing lipid metabolism this variable may be valuable in future assessments of disease risk 
in menopausal women. 
The results also demonstrated that the ME women were heavier, had a higher BMI and a 
larger WC. As mentioned before in the review of literature, a large percentage of women in the 
Iranian population between the ages 55-64 are considered either overweight, obese or 
abdominally obese, as per the WHO BMI and WC guidelines (Janghorbani et al. 2007). The 
findings of this study are in accordance with the results of previous studies. 
PA levels were measured objectively through the use of accelerometers and were also 
measured subjectively using the self-reported HP APQ tool. The accelerometers did not detect 
any significant differences between groups. Step counts were comparable as well as EE. Activity 
counts, the measure of the exercise intensity, was slightly higher and more variable in the W 
women compared to the ME women but not significantly different. Based upon the HP APQ, the 
W women generally took part in more intense physical activities, which may have contributed to 
their healthier body mass, BMI, WC and a higher V02 peak, even though overall EE is not 
different between groups. The HP APQ asks questions about the frequency and intensity of PA 
plus the respondent's perceived fitness. Depending on the response to the questions, points are 
allocated accordingly higher score is representative of a higher perceived fitness and PA levels. 
The HP APQ can be found in Appendix C. The W women scored higher on the HP APQ and 
reported to participate in higher levels of PA and at a higher intensity then the ME women. As 
well, they had an elevated perception of their physical fitness. This can be related back to the 
results of the accelerometer which suggested that the W women tend to participate in regular PA 
for health benefits, while ME women tend to participate in PA for leisure purposes only and not 
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for the attainment of health benefits. The ME women may not perceive the activities that they 
participate in (household chores, walking etc.) as activities that are beneficial for their health and 
as a result underestimate their PA levels. 
The accelerometer data revealed that the W women participated in higher intensity 
activities, even though the total step count and EE between groups were similar. The higher 
activity values that were obtained represented a higher frequency and intensity of PA 
participation. Upper and lower limits for what was considered low, moderate or high intensity 
was not provided by the accelerometer manufacture. A simple comparison between the data has 
been made which has shown that W women have a higher activity count than ME women, leading 
to the conclusion that W women take part in higher intensity PA than ME women. Another 
finding from this study was that ME women subjectively rated their PA and fitness levels lower 
than the W women. This illustrates that ME women do not perceive themselves as being healthy 
and physically fit. This may be related to the idea that ME women are aware that they do not take 
part in organized PA for the purpose of improving their physical fitness. 
Al-Nozha et al. (2007) measured activity levels in the Saudi population, a sub-group of 
ME, and reported that 98.2-99 .1 % of women between the ages of 50-70 years of age were 
inactive based on minimum of 30 minutes of moderate intensity PA at least 3x week (Haskell et 
al. 2007, Warburton et al. 2007, Tremblay et al. 2011, WHO, 2010). Al-Nozah et al. did not 
speculate on the low PA participation. Merom et al. (2012) compared the activity levels between 
Palestinian and Israeli men and women, and concluded that Palestinian women expended less 
energy during moderate to vigorous PA compared to the Israeli women, therefore implying that 
Palestinian women participate in lower levels of moderate to vigorous PA in comparison to Isreali 
women. Palestinian women received most of their PA from household chores and light to 
moderate intensity walking which was reported as their leisure-time PA (Merom et al. 2012). It 
can be seen from these two studies that ME women do not expend much energy in moderate to 
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vigorous intensity PA, which supports the findings from the present study. Walking and 
household chores are the two most common forms of PA that ME women engage in. 
6.2 CARDIOMET ABOLIC CHARACTERISTICS 
Resting BP, HR, V02 and exercise HR peak and V02 peak were measured for each 
participant. Resting measurements were similar between the groups. No significant differences 
were observed among absolute V02 peak and HR peak. Relative V02peak was significantly 
different between the two groups. The measured V02 peak values in this study are comparable 
to the V02 values measured in other studies using similar study participants. Johnson et al. 
(2010) measured a relative V02 peak of25.5 mL02 ·min-1•kg in postmenopausal women, which 
falls in the middle of the V02 peak values of the ME and W groups in the present study. The 
values from Johnson et al. (2010) coincide with the measured values from Numao et al. (2009) 
and Zarins et al. (2009) V02 peak of 25.3 mL02 ·min-1•kg and 25.5 mL02 ·min-1•kg respectively. 
The peak exercise HR attained during the incremental to maximum exercise test in the 
present study demonstrated that the ME women were not able to reach their calculated age-
predicted max HR whereas the W women did. The mean age of the ME women was lower and 
therefore their calculated age-predicted max HR is higher. The ME group had a measured HR 
peak of 158 beats per minute (bpm) while the mean calculated (220-age) HR max was 167 bpm, 
the W group had a measured HR peak of 164 bpm and their estimated HR max was 163 bpm. 
This demonstrates that the W group was able to tolerate higher intensity activity which is 
supported by the results of the PA measurements and participation in higher intensity PA. 
6.3 HORMONE AND LIPID PANEL 
A wide variety of sex hormones were measured and compared in this study and no 
hormonal differences were detected between groups. Studies that have measured sex hormone 
levels in women pre and postmenopause have mainly been breast cancer research studies. 
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Researchers that have looked at the ethnicity and breast cancer risk have measured sex hormone 
levels and compared them between ethnicities. These studies that measured sex hormone levels, 
observed ethnic differences in estradiol, testosterone, FSH and SHBG both pre and 
postmenopausal stages (Randolph et al. 2004, Santoro et al. 2004, Setiawan et al. 2006, Sowers et 
al. 2006, Sutton-Tyrell et al. 2010). Ethnic groups that had been studied include White, Hispanic, 
Chinese, Japanese and African American women. ME women have not been studied and 
therefore the hormone measurements that were obtained in the current study contribute new 
information to the body of literature on women's reproductive health and menopausal transition. 
When comparing the hormone and lipid values of the ME and W women to that of the 
laboratory normative data, all of the measurements fall within the acceptable range with the 
exception of LH and LDL-CH levels. LH levels fell below the normal range; the measured 
values are being compared to the normative values that Canadian Life Labs uses. The values and 
ranges set by this laboratory are specific to this lab and may differ to the normative values of 
other laboratory (Canadian Life Labs). HDL-CH levels are again elevated above normal for both 
the ME and W groups. The normative values for the lipid panel are not just applicable to 
menopausal women but these values apply to persons of all ages and sex. This study was cross-
sectional in nature, which only provided a snapshot picture of the lipid profile of the study 
participants. Premenopausal values for the lipid measurement were not obtained and therefore 
not available to compare current values to. This comparison would provide a better 
understanding of the changes that may occur as a result of the menopausal transition on lipid 
profile. 
6.4 FAT OXIDATION 
Contradictory to the hypothesis, differences were not observed in resting FOR, FOR at 
varying sub-maximal exercise intensities or FORmax· This study acquired data on the FOR of W 
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and ME women over a wide range of exercise intensities that allowed for the data to be fit to a 
curve and provide information on FOR, FORmax and F ATmax. Once again, to our knowledge, no 
other study has investigated FOR in ME postmenopausal women. 
The FATmax value obtained from the current study of 49.3% V02 peak and 44.8% of 
V02 peak for the W and ME women respectively do not coincide with the F ATmax values that 
are similar to what has been reported in other studies of sedentary W females that utilized a 
treadmill protocol (reference). In younger and more fit populations, Atchen et al. (2003) had 
reported a FATmax at 59.2% ofV02 peak and Cheneviere et al. (2010) at 57.2% ofV02 peak in 
treadmill exercise. The treadmill protocols used by Atchen and Cheneviere differed slightly from 
the protocol that was employed by the current study and the participants in those studies were 
different. The study participants from the previous studies were healthy young men and women 
that had healthy body mass and BF. As mentioned in the review of literature, age and gender are 
influential factors of FOR. The FATmax from the current study with the FATmax of the previous 
studies cannot be compared due to inconsistency of the protocol and study participants utilized in 
the studies. FORmax had not been measured during incremental to maximum exercise in 
postmenopausal women until the current study. Other studies (Treuth et al. 1995, Zarins et al. 
2009, Johnson et al. 2010) that have examined FOR in postmenopausal women have only 
measured FOR at rest or at single% V02 peak. This has made it difficult to compare the results 
on FOR, FORmax and FA Tmax of the current study to that of others thus making this study novel, 
in providing detailed information on FOR in ME women. 
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7.0 CONCLUSION 
In summary, this study contributed to the ever-growing body of literature on fat oxidation 
and women's health by exploring an ethnic group that has not been studied previously. 
Significant differences were not observed between resting FOR, sub-maximal exercise FOR, 
FORmax , hormone levels, height, body fat%, skinfold measurements, HP APQ, resting BP, 
resting HR, resting V02, HR max, fasting blood glucose and fasting blood lipid panel. 
Differences were observed in BMI, body mass, WC, age at first and last menstrual cycle, age at 
study participation and V02 peak. As a result of this research, new information was reported on 
FOR and hormonal characteristics for ME and W postmenopausal women. The current study is 
one of the few that utilized a treadmill protocol to measure and calculate FOR over a wide range 
of sub-maximal exercise intensities and provide values on FORmax and FAT max. In addition, this 
study is the first to examine FOR and FA Tmax in ME women and to measure the hormones that 
may impact fat mobilization and oxidation during exercise 
The next step in addressing the cardiomefabolic risk factors that seem to linger among 
ME women is by addressing preventative strategies to reduce risk development. This study did 
reveal the differences in PA participation, W women participated in higher intensity activities 
than ME women. Regular moderate intensity PA has been associated with health benefits and 
high intensity with greater health benefits (Janssesn and LeBlanc, 2010) in body composition, 
blood lipid profile and BP (Gledhill and Jamnik, 2003). Encouraging ME women to take part in 
regular PA for the purpose of improving their overall physical fitness and health with allow for 
improvements in risk development. Developing cultural-specific PA strategies will allow ME 
women to freely participate and incorporate regular PA into their lifestyles. As mentioned before, 
regular PA for the purpose of improving one's health and physical fitness will allow for risk 
reductions in cardiometabolic diseases. 
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This study has some limitations that should be noted. First, the sample size was small and 
this may have had an influence on the lack of significance of the results. With the results of this 
study if one were to perform a power analysis, in order to attain power at the 0.05 level for a two-
tailed alpha with an effect size of 0.8, the number of participants in each group would have to be 
60. Second, the participants were chosen at random and were not matched for any variables, 
which could have confounded the results. And lastly, diet was not recorded or controlled for 
which does have an influence in the outcomes of the fat oxidation protocol. 
This research study has shed light on FOR within an ethnic group of postmenopausal 
women who have not previously been investigated. As well, information was provided on FOR, 
FORmax, F ATmax using a treadmill protocol and hormonal measurements for ME and W 
postmenopausal women. A treadmill protocol was created and used which provided whole-body 
FOR at multiple sub-maximal PA intensities. PA levels and anthropometrics were also obtained 
in this study providing detailed data on the health and fitness characteristics of the study 
populations. The current study was exploratory in nature and offers a concrete basis for future 
research. Expansion on this study will provide a more complete picture of how the menopausal 
transition affects FOR at rest and during exercise in ME and W women. Following ethnic women 
longitudinally over the menopausal transition tracking FOR at sub-maximal PA intensities, sex 
hormone levels, PA levels and anthropometric characteristics would provide a better 
understanding of how the menopausal transition influences a women's physiology and disease 
risk. 
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APPENDIX A. Physical Activity Readiness Questionnaire for Everyone. 
PAJR-iQ+ 
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B.eing more phfr.;ietll)' :;~is ·v.f!<:ty safe for ~lr people. ii~rrls, q...i~icnmnim will e.ell ycui whether it is il1etl!Zi!ry bj ycH..1 to 
~t:ek !wtthet Ztdvice ·from. your doctor OR z. q11Dlified c:x~:s~ jprol'i:zional bcfote becoming moc-e ph)"!lic:lify .active-_ 
SECTION 1 - GEr\JERAL H ~ALTH 
IPleitl!S• rud :the 7 .gunsticrB below ara!fu'!!Y._ zindl ;Bl'l5WIJI" GD !Dnlt lhonedy: dwtc:k va. or !NO. YiS 
_D 
..., De :~:i fecl FJ'lin tJ1 your· dheit at i~. during yew dail).• i.'!tdlivrne:s, of living·, OR '#ohm )\llt.J do ~ical 
Le ildiWty? 
Do )'C!J Im!:! balance lbcco:uz;-1,?' af d:uioo~ OR hln'C :yccJ lmt.·c0:"'1sciC1l9!i.llC!i5iii11.ite a.mt 12 mcmth::;? l?1~e: 30 ill"'15Nlcr· NO if your dizz~"ll!S5 WilS im50diJ1ed wili'1 CJVCrabmn+ii~ Ontlbdl.n_a du.~ vi_g_om1.2; c-mrds.c]. 
4_ Have ycit.w ever bee'1 di11goo£ted ~ .ooolt!.,, dYon!c: meeir:al cooditi:lfi (olttaf ~~ heart d'8~e or· hlgl-! ib\xid J)feS&Jre]? 
~ ~ . ·---- ·- -. -· ··- - ... ·- -··-· -·-· --· -·---·- - . -·-- ·-- - ---···-·-.. - - ·- - .. -
S. Am )'OU ~urmntly tiJOng pre5Cribm ~'tiarris fur .a duooic mcdic,aJ C()nditiolil? 
Do .toiJ ~ B· booe or Joki~ pf(!blern d~t roul'd' be roadie W<li'le.~ by DeCf>'l°!iirtg !friOf·S- ~hfak:~ ~'tt'? 
6_, Pleae& ~s.wer NO if you had' ajoim. problern in the 13.,.t .. b.Jt It do01S oot litl"'irt 11)Ur oonr&r1b .abillty to be 
~k.n__!l:i_ adi'wl. Far, exa~e.. !lo!i~. ankle, !:i'lc:ruldl?r' er o'ihacr. 
• > Smrt lb~mit~ much mere phySK:.nlly a.::ti·m =:start .*1Jit .and build: up· gm:l11Dlly. > Follow the C:a.;&:lizm P~")'!iic:al Adi,.ify· G:.iidelines mt y.our ag!! 11W~~.c:al~gmlinf!S). > Yau may m~I!' part in .a lht!ithh .and !:1mem ~t.ni!anl. 
> I! yo11 ~rm>e :nr"J' furt11et qi.est.iotd, ccnt.a.ci a qut1lif'ed exetci5e profe!S!Sional1 such :ns .a 
CSEP Certified En!rd2 P~ofogist• {CSB?~EP.I<-
> If you .:ir.e a.-er the age of 45 :;rs. :md IN01"·iKqJstomi:d to reg,uls vigorous p.~ital ll<:tMI.}~ 
please ·cott5uJt .a qJ;;&fie.tl exerci2 pdesmm~l 1LCSE~·CEPlt be!tu'!! engaging in rttaKimi!A' e~art 
ex~n:i~e. 
De!lny bemrri:ng more active rf: 
Jo Yi::lu .;re r<!Ot fe~ittg Y'.-ell l:::.ed-..ise of ii!! tertcparr21r1 illrt<ess suthi ~s .a to'Jd :er ·f-eyf"!j ... ·W'Zlii um.fl :,-o-..i 
~el better 
~ ~u Mt: [pri.>gm::rn"!.,.., u:ilk tc ·ycur ltu::alih ca,-c prat:'titicnerr )'OJr p.hys:dan .• a q!£.!lifir.:d !!;u:rd:i.;c 
pnJi'e!i?lkinal. lllidlcr cornF:4et~ t:J1e PAP.rned~X fo; i?ut?gnaocy !bdcre- be.::o-'litcfil mere F~,ysically 
i!!ictiveOR 
> "ITT::lut bezt!1h dii'll'lge5,.,. please 1Bra.o,r11"t!r tl-ce t;ulS'ticns 011 Setttorn 2 of ·this doO.JmerJt .artdliar talk. ~a 
yew doctor o; ql.!l.:tlified l?!Xen::i!!ie pr.::ifezicnal (LSEP..QE!=~ lbt...f ore co11~ini.C,,51 wnh any p'hys:'..:.al 
~-tivi'!y prograrrme-. 
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flHM Ned ttw ~ b!P.aw ·mt-lffQty and •l"l'n'Hf •iKh om.1· ~n11stl)'; .m.i.k ~·or NO. "ti5 NO 
LJ LJ 
, l);J.)'QY.1-..,.,.. Artfirftis;, 0s~"11Si'1,.. r;,r· ~de. P'TIJb~l' lf)11~ ~rtJWi!f lf~.goto 
q~ ffn'dlt!r't 2 
, ... ,c 
Oo )".:'\! ~ d•raJl';fiXlifl'troiliog ~"::'l.l'«rd!tion "!lrith ml'Jdiljll;~ or~ 
D D .. .,, phpii.1"1J?'l!ltr.1'~ed ~ia1r ~.nS!lftlr NO r ~'Ol! ~artot i:;\.~..;•; tl!ij"!I 
ITH!ldiati Cil'1lll! r;,r other ~ b"Tll!r!bl 
i'Jo )'CN ~joint pmbliti'N Qi.dW:J pr."' a mor1dramilll M ~ f.atilild 
·~b. to,-~· or ~f', d~nced ~tl-e.SJ .. e:poodybl~~ aMJ/ D [J ~ lfX"~~WJ»!ll; d~.?1> r;ndii i!'i the bony r;ng Oil the ~. iif~ r-P~I 
rrolumnl? · 
le. H&-,iii )'CU had st.lltoi'.:! irljliciJ~ &Ytakitt\ sw.oid r:.ibllffS JD~wl)• fer imarit it'i.11'1 l D D iroomhl:? 
D D 
2. Oa '.Ji'Oi.J h.l;,'* OOOll"af ~,kind? If Y'l~ a l"Ftt'Jf IF oo. §i1C1 IX\ q~ qisast'4.,., 3 
~·21o 
2'11. Do.a~ )'OOl'miliW'ditgneais. lodudit &ff)• Ci n il0tlr:wd119 ~fl'd! lta\91broodYJglltliC.. ml•-.i:tla rmelo.rnn ~"'.l!f crfplMrnl r:elsl, be.d. Fid nr.tdc? D D 
2b. hflJ. YQl.I. """'l!Hldy ~nsw Qlr~·tfier~ budi !!!~~"'~PY'« r..dknt•.fP'il? D D 
·-. 
~~ ..• .. --·~ .~ .. 
O'.J. you hra.l• Hean:Oll·lllH 01Cw.SmY.QllOll1r~? D D 
:1. Th"s lndudia.t Ct::..mrwi~ tU1111iH. ~ (lkffxl hrmUfll', HIH'il'E F\i.ik.im~ Di-entMild If )ii:la ifOW!lf ltna,.goro 
Abnam-.J~· cl Hurt m. .q~ t~.Hlflkri '4 
>.Y. 
--
.. ... ~-
" ·~ ~~ .. 
Do )'Clll hiMe dillaJ~O'".AlrtroNlng )a.M!·a::ndttk:m'lil'tih ml)dic.u.kafts ~ cdlw 
D D 3a. phpcian~ d'Hr11ntpiad 
t,/wJINM' f\f'O If~ IN: f).Ctl(Qi~ t.d:•~ IYH'ldimiiOO& ct'·l'Mhtt i11t01l1'fllt'.U~ 
:Ml. Oo )'QU h:wtt nn ~·lR h•1.rt:btH!t lhl.i! requirM m'.tclic..wi m11ri.ngaml!Hlt? LI D (&.._q. DiM britlWtkm, ~ wnaicuilar~u.) 
:k. Do }'CIU fvMt chranic hiHn f 111for11:? D D 
:?d. Qo )'Cit.I h.t.v. a rtifhg blood pMwn illqWll. ro m fr'li"r ihaft 1a1r;(J l'!'lll"fig 1'rhh or 
•.vllhour: l'Nd~ni' (Ans.;.1u 'tt't!S ''~de. nai tn.::FN 'J!(H.lr i'tilljng ~oc.d Pf'iliS:D..l'wJ D D 
le. Oo ~ J-w.ttt d~ed ~ 1rt.1Jry·~-:nrdi~ut.J d~ and '1!ll\1f not: pamcip.Miid In ~iv pt~kal iiM.-.h-~ in 1h11· la 2 rru.ihs:? D CJ 
4 Do~~ .... """' f'Alo41ttofk: Co!Y.:lilliol1'5? 0 0 111 Jti~ ilfmwlii' l,oo .. ~ro 
tlri$. lndi..ldes 1'JPlt 1 CMabatn .. T~ 2 Oiaibliri~ Pr~labar.H F.f~ &'!f.Hli OOfl 5 
4M«:: 
-te. le: ~r blood s:ugiK ~ abi:r.tl! BJl 11M1oUl? (An!P'Mr VfS f ~400 ere il'Wt SJ.J"t!:! D D 
.Cb. 
Oo ~~arty P$7B t1r S"FPt~ of' ocii!lbetM r:ompiimticrr; PAii..., 1'-.1t:,'1: 
u lJ ~r 1,...a1br d~ aodlar ~piCJl:~ ;s~-tin!i :r'OUr e·~"H., k~rs;, ll"'id the 
1l!ll1Hllktn " your Wm .-.r::I iiM't'i' 
4c.. "1J. )'QIU '"1.a.lM oih11:r tl"'llUbolk: o:'.lllY.lti.ioos t;iud-1 ilS ~d d:iadaaf:ii .. pN£fWRCJ- D D iit1~ diabe--. r,;hn:;.oii:: L;idn:~_di~'"'· h."l!ll" ~~~!IF 
0o :fOi.J h;i.,... lli"Ji' P..w.ul H:Hhh ~ or L1u1miftg Oiffir..J.Jti11s.? 0 D 
.5 .,._,s. indudti .rafahiJlmliin,. o.rr.itia, D.pras.sioo, AA'Liliil}' Oiv •. trdtt; EJt:ing D~~ • lf·,.,:s.. l!IV!'Mf if 00. go to 
~ ~sr.a11·dPJr .. i-4'1tl;K;Wal DAbilw1-~ S)T"-0.~ qiJK.tr •• 115· Q.testi....,..., 6 ~-~ 
Co )'OIJ h.t~ dliloui.) comrolilig '/LU',t:.Cf".dilkm ..iih madat:On:S !lr Ol'J'tw 
0 D 5e. ~-Frian-pcl.twjof.td ~i,n? rAn~r NO ·c: :fill! l.W'D n;:rt r;v.tTl!nl;~ rttrlfo!i 
~i~tions tr other 1.re'll~1I 
5b. IOo ~'CIU ;slso h~ l»dc problerm1; trffe-cfrg ~er imi.m:les.'? LJ [J 
-
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IPhll•M n1ed 'tM ~!'Tl· bfiaw ·Filtr~ 1~ .. mw11r eam onliJ· hoM~b'; ~k YES ·Qr NO. 
Du }'Cl.ii t-... .,..,"!. 21 R1!5Pr;J':..-.ry J~~? 
6 -..;:; i'ltforJe-5 (h-.:ink·O~rtrM P'1JJcnDn1'"J I)~~. A.rtt.r~. Pukm:m~"J' :ttg.'i IBliK'd 
Prt"m.1nt 
iOo ~ hsa,re r:fEro'!':-1·00."Tln:i!Fi;a "Pif'·~iti;:m·~ith· rnerft't!tb:n ~r ~r 
Ctl. l~?;irf,;an-prewraf!d ~~i.,s? 
r!!J.'1fJ/Nijl· l'>IO if)'l':'J ;;mt n~r!tirtkrl1!t_ ta:i'lQ tmtr!lli::.rt.i~ ar· !!ihc:r'ihhl~t't!il 
Hi:i ~ur doc:!lr 11'Wlt.':5i.ll:t )OOr bbocl ~)'gfdl iwr.l rs. b ... ·.u:fim e1 .m.t~ ~111ra:Mi 
~thlt}"fl_U.~re<.51Jppltwntt"111l~e11 thl!!-r.!P;'? 
ti .&':ttMMk, ·!!~ i,v.i1.1 i!ili'i'untll'• hi:i•'IJ ~~YCl"!tl of ~.i; 11igh~ li.~lin~ l17itt~ 
6:.. i!>fN~ng.. c!lnsisuint coo£ta (fr.a-Iii 'thi:lri :Z dlf(£•1v.~ Cal' hll'111.1 'jCAJ ~ ~ rtdt~~ 
lfrt(r!lit.uioo rru1:1 than t.Mm in 1ha li:i.l:w~? 
lill'$ ~Ur d.oc":i1r ~/f!'l'."Rli::l "f'DU· hi!'!!"& hti-:i'1 Ch.X . .f ~~e ·r,~ t'hll bbcd Y-IJ'nel!l of' 'j!~ 
.U.191~ 
: iGo'~'tl'I.! ~ .. ., ditf'aJ~'JM.~vTt.rtilirt;J ~-07lditkm'tl!itf1. rner.fo1~i..~ rDr 0c':hef 
'Jr.. I t!>h)'Siei.in-pr11S£1i!J.i1d ~fiiiS"!'. ' 
: ~ N•:lt if)i:i.J ;ar11: n011.>!.01HdYi11_ ta.k~ lfi'Hidit.iiieB5. Ci'•ili:t11:i'"irih1ll"Mi"tUI 
"1b 1 Do)":IU c:~ly«thmit IOllV !"K':'hw ~IDIX:I p~tl ~g..,?1csr~ ien:tl_~h·to ettt'Sf! 
• 
1 itiiu~. li!T~-hl'!!tKil!~. andtor 'intir.g~ 
'}.:.. HH )'!JUr p'h:,sklWi f~a:Mild ~':,'.fOU aihib::: 51..ddtlft booUi r::fi hi!ti bbocl p-~surit 
~'ll'J-"!Tili IUAvtQl"AJl"T!t.:~m~LJi? 
;g_ Ha.Vii roo h~ a ~troluf't 
Tl-15 indudt-5 r !llnsitutl. hd:<l!r.-;r;; A':'tlt~ t;if~ti,) or ~br.U\inru ~r Ev.r.:rrt: 
Co .rou hive dM i:1.1ey.mriirol ling ycu .ca::i"'idnkln ...n'th mcd~k.trdi <!if drW 
Bti.' ~ii~rt-pu.!WmeG ~ins? 
:',h~ ~O if)'tl.J ~!'I!' nt:11 ~~ ~':~~ i:nerit[;!D~i!!l r.:.-:aJT!le''Ul!:,~1 _ 
~.. I)., fCii..i M"!'!' nrrr r:t.'1'l"t '!led° ad ·i::-on;litioo nr;.~ I l1ted .ebi:!'.1!1 r.:.- tilo YQl.! T've wHh f;f.iiJt·r::bri!rii-Li 
ccod-:ui:ii! · 
HF1e "pi:;.1.i! l!!iipanett~ .ri bbJd:01.t.. or l;::rt W:v!lsc· r:it.r~ ~s; a 1~t:m.1lt i::;f;, fhf!.!<I 
'J"o). 1"'.1ur1 Ya!"'J1ir1 r.hc i.lst ·r 2 m!lnlh:ii ~ ~ .. ,. y!.lu hax! ~ d:.afrr:rsocl ei!.ln~oo wittln tl-...tl: 
il:isc ·~ 2 moor:h:ri? 
9b. :0.IJ' ~"01.I h.1.•.re ~ metfr.:..ei oom:iitir.m t.h11t is; no": 'is~ 
1;~ ~ ~· e~ nf!uro:O~t~! -:~:~. J,c_itinf!~ proo i:r-~~1? 
YES NO 
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'!;~_;j ~li-..::n"l 
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1 ... 1c. 
D L1 
LI D 
D D 
D D 
lf·im~. ~"'?!\'ll:f rf ~.go 1;o 
q Lff'5tQ'i s. i::pjlt!sNl"'! 9 
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0 If fQ.iU ansWll'MI. . HO.· IEI .all at 11111:.~p 1!JUil5datB Klf:(Ut yo11r.nnadlcal cond. ··  llfmt, ya111-. r•11aly·1m bteCiYi·I ifiOi'it PhW'~ te:j¥e;; ~ It l& adwt5ild !hat jlOiol cl7tsult .a. qtMllt&d ~ ~.loNil (11'.g .• a CSEP'.CEP) to help !fCU dwelcp a 
stl1e et'd •~ p~~· aCIMcy plM to tfltet )'Ot..11' tn:seh.ti ne!N:b. 
1 Yoo are fifll'WXUagr.il l'O stun :Sb.t/ and bul·ld up gr.adual~· - 20-60 mfrl. a·f LO'N• to modnra!Et ... r.tM't!ltty 
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PKI' ... murt..bo-9!71'1hiJ ~ 
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APPENDIX B. Informed Consent Document. 
Informed Consent 
Ethnic Variations in Fat Oxidation Rates Among Postmenopausal Females at Rest and During 
Exercise 
Veronica Jamnik PhD, Michael Riddell PhD, Faiza Abdullah MSc Candidate 
Kinesiology and Health Sciences 
Contact email: afaiza@yorku.ca Office phone: 416-736-2100 ext. 77236 
Purpose of the research 
The purpose of the research is to characterize the fat oxidation rates at rest and during exercise in 
postmenopausal females from the Middle Eastern and South Asian communities. The participants 
will undergo a series of incremental to maximal effort exercise tests to determine their: V02 max, 
peak fat oxidation rates. Researchers have made the connection between a low fat oxidative 
capacity plus fat mass gain and an increased predisposition to cardiovascular and metabolic ( eg 
diabetes) disease . We will be examining a number of hormones in an attempt to link the factors 
that influence the weight gain observed in postmenopausal females. Research has been conducted 
on fat oxidation rates of Caucasians and African-American females, but there is limited 
information on the Middle Eastern and South Asian populations, although related research 
findings suggest that these ethnic groups are likely to be anomalous and consequently at greater 
health risk. We hypothesize that the postmenopausal women in these ethnic communities have a 
diminished fat oxidation rates, contributing to the increase in fat mass, especially visceral fat 
mass experienced with menopause. 
What you will be asked to do in the research 
Once pre-exercise clearance has been obtained using the well-validated Physical Activity 
Readiness Questionnaire+ (PAR-Q+), the participants will attend the laboratory on 3 separate 
occasions to undergo exercise tests on the treadmill. Qualified exercise professionals (Canadian 
Society for Exercise Physiology-Certified Exercise Physiologist®: CSEP-CEP) will conduct the 
exercise tests. 
Prior to the exercise tests each participant will have their resting blood pressure and heart rate 
measured. Body fat percentage will be measured on the Tanita Body Fat Scale, waist 
circumference, height and weight measurements will also be taken. Also, blood samples will be 
taken from the participants at the second session when they are in a fasted state by a certified 
phlebotomist who has medical delegation to characterize their blood lipid profile (HDL-
cholesterol, LDL-cholesterol, triglycerides, total cholesterol, glucose) and hormone levels 
(estrogen, progesterone, testosterone, follicular stimulating hormone (FSH), luteinizing hormone 
(LH), insulin and cortisol). 
Urine samples will also be obtained from the subject for comparison to hormone levels in the 
blood. The urine samples will be collected in laboratory containers while in a fasted state. 
One of the exercise tests will determine the participant's Aerobic Power (V02max) and consists of 
an incremental to maximal effort graded exercise test on the treadmill, during which the 
participant will walk on the treadmill until she reaches volitional fatigue or until the tester asks 
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her to stop. This may take anywhere from 10-20 minutes in duration. The second and third 
treadmill tests are sub-maximal in nature and will be used to determine each participant's fat 
oxidation rate. The duration of the 2nd and 3rd treadmill tests is approximately 35 minutes. During 
the treadmill tests each participant will breathe into a mouthpiece and heart rate will be monitored 
via an electronic heart rate monitor. 
Risks and discomforts 
Taking part in any physical activity has some minor risks such as fatigue, soreness, or shortness 
of breath. To minimize these risks, participants will be required to complete a pre-screening PAR-
Q+ and the physical activity will be supervised by exercise professionals (CSEP-CEP) who are 
qualified to conduct safe exercise tests on people with and without chronic diseases. 
There is a very small risk of infection with the blood collection. All blood samples will be taken 
by experienced and qualified blood samplers (medical delegation) using sterile equipment and 
techniques. There may also be minor discomfort and/or bruising at the needle site. 
Benefits of the research and benefits to you 
The participants will better understand their health and the benefits of regular physical activity on 
their health. If unfamiliar, they will become accustomed to walking on a treadmill. They will be 
given information on how to stay physically active and on how to adopt a healthy lifestyle. 
Voluntary participation 
Your participation in the study is completely voluntary and you may choose to stop participating 
at any time. Your decision not to volunteer will not influence the relationship you may have with 
the researchers or study staff or the nature of your relationship with York University either now, 
or in the future. 
Withdrawal from the study 
You can stop participating in the study at any time, for any reason, if you so decide. Your 
decision to stop participating, or to refuse to answer particular questions, will not affect your 
relationship with the researchers, York University, or any other group associated with this project. 
In the event you withdraw from the study, all associated data collected will be immediately 
destroyed wherever possible. 
Confidentiality 
All participants will remain anonymous and the results will only be reported in aggregate format. 
All hard copy data will be stored in a secure filing cabinet. All participants will be issued ID 
numbers. The participant's name and corresponding ID number will be securely store separately. 
Computer based data will be stored on a secure system with identification by ID number. No 
individual data will be reported in publications, and to meet scientific standards, the data will be 
kept for 5 years following the publication of the study results then destroyed. 
All electronic data will be password protected and only research personnel will have access. Hard 
copies of the data will be destroyed using a confidential shredding agency five years after 
publication of the study results. Confidentiality will be provided to the fullest extent possible by 
law. 
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Questions about the research? 
If you have any general questions or questions about your role in this study feel free to contact the 
researcher at the above email or phone number, or contact the supervisor Veronica Jamnik, PhD 
at ronij@yorku.ca or at 416-736-2100 ext. 22995. 
This research has been reviewed and approved by the Human Participants Review Sub-
Committee, York University's Ethics Review Board and conforms to the standards of the 
Canadian Tri-Council Research Ethics guidelines. If you have any questions about this process, or 
about your rights as a participant in the study, your may contact the Senior Manager and Policy 
Advisor for the Office of Research Ethics, 5th Floor, York Research Tower, York University, 
telephone 416-736-5914 or e-mail ore@yorku.ca 
Legal rights and signatures: 
I, consent to participate in 
Ethnic variations in fat oxidation rates among postmenopausal women at rest and during exercise 
conducted by Faiza Abdullah. I have understood the nature of this project and wish to participate. 
I am not waiving any of my legal rights by signing this form. My signature below indicates my 
consent. 
Signature Date 
Participant 
Signature Date 
Principal Investigator 
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APPENDIX C. Healthy Physical Activity Participation Questionnaire. 
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APPENDIX D. Individual fat oxidation rate curves for each participant compiled onto one graph, 
separate for Middle Eastern and White women. 
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APPENDIX E. Raw data measurements for each participant. 
Participant Age Age of first men Age of last men Height BM BMI WC 
(years) cycle (years) cycle (years) (cm) (kg) (cm) 
WhiteOl 66 12 52 154 68.4 28.8 86 
White02 57 11 50 150 51.6 22.9 86 
White03 58 11.5 55 158.5 68.4 27.2 91.5 
White04 52 11 50 159 68.l 26.9 86 
White05 56 11 46 158 65 26.0 94.5 
White06 56 13 52 170 63.9 22.1 81 
White07 62 12 53 159 52.6 20.8 77 
White08 56 13 53 168 99.6 35.3 114.5 
White09 54 13 49 161 71.1 27.4 84 
White IO 55 13 52 163.5 76.1 28.5 97.5 
Whitel I 60 12 49 162.5 76 28.8 83.5 
Participant Age Age of first men Age of last men Height BM BMI WC 
(years) cycle (years) cycle (years) (cm) (kg) (cm) 
MEOI 52 12 38 168 85.9 30.4 106 
ME02 57 14 54 176 99.1 32.0 113 
ME03 53 14 46 162 76.l 29.0 100.5 
ME04 54 12 51 154 72 30.4 101.5 
ME05 51 42 164 82.7 30.7 105.5 
ME06 47 15 45 162 109.2 41.6 122 
ME07 49 13 37 161 101 39.0 118 
ME08 55 14 53 158.6 94.2 37.4 117 
ME09 53 14 50 162.6 68.1 25.8 94 
MEIO 54 12.5 50 156 51.3 21.1 84 
MEil 54 11.5 45.5 160.5 84.2 32.7 106 
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Resting BP Resting BP Resting BP Resting BP Resting BP Resting BP Resting BP Resting BP 
Auto LA Auto LA Auto RA Auto RA Manual LA Manual LA Manual RA Manual RA 
Participant Systolic Diastolic Systolic Diastolic Systolic Diastolic Systolic Diastolic 
_{_mmH_g) _(mmH_g}_ _{mmH_g)_ _{mmH_g}_ _{mmH_g}_ _{mmH_g}_ _(mm~ _(mmH_g}_ 
WhiteOl 119 73 115 70 104 74 102 72 
White02 157 83 143 77 136 86 140 82 
White03 102 69 113 74 108 68 104 64 
White04 110 75 115 73 110 64 106 62 
White05 98 53 99 59 96 58 100 60 
White06 141 91 146 91 140 78 150 80 
White07 101 59 97 58 92 52 90 58 
White08 110 75 113 81 110 74 110 70 
White09 105 72 103 72 110 62 102 68 
WhitelO 102 68 105 73 102 68 98 60 
Whitel 1 113 74 121 72 104 62 112 64 
White12 111 79 118 84 120 72 110 74 
Participant Bicep Tricep Subcap Illica Medial Total SF CPAFLA CPAFLA Body 
SF SF (mm) SF (mm) Crest SF Calf SF (mm) Score Rating Fat% 
(mm) (mm) (mm) 
MEOl 21.1 25.3 23.1 25.2 30.l 124.8 0.8 Fair 43.5 
ME02 18.3 25.2 37.3 28.3 22.5 131.6 0.8 Fair 45.8 
ME03 9.7 22.7 21.2 30 18.9 102.5 1.8 Good 39.4 
ME04 8 21.5 21.4 15.2 17.8 83.9 1.2 Fair 37.3 
ME05 15.8 30.9 19.4 30.6 30.4 127.1 0.8 Fair 45.l 
ME06 38.8 28.4 49.4 45.3 45.6 207.5 0 NI 47.2 
ME07 28.4 37.8 39.8 47.1 42.7 195.8 0 NI 47.7 
ME08 23.7 37 30.9 56.4 54.9 202.9 0 NI 47.3 
ME09 13.6 24.7 26.1 23.5 18.9 106.8 1.8 Good 34.7 
MElO 7.5 15.1 13.5 14 9.5 59.6 3.4 Ve_!Y Good 27.4 
MEll 14.7 26 37.7 41.8 34.6 154.8 0.4 NI 43.1 
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Participant Bicep Tricep Subcap Illica Medial Total SF CPAFLA CPAFLA Body Fat% 
SF SF (mm) SF (mm) Crest SF Calf SF (mm) Score Rating 
1mm} _{_mm} _{_mm} 
WhiteOl 10.4 16.4 22 19.8 17.4 86 3 Ve_!Y Good 36.7 
White02 6.6 15.3 19.6 23.5 15.3 80.3 3.4 Ve_!Y Good 31.3 
White03 12 24.2 30 20.5 18.5 105.2 1.8 Good 37.4 
White04 12.6 16.7 21.5 21.7 23 95.5 3 Ve_!YGood 35.3 
White05 16.1 24.9 23 22.9 22.9 109.8 1.8 Good 35.3 
White06 6.7 11.1 16 13.9 11.4 59.1 3.4 Ve_!Y Good 31.2 
White07 7.8 15.3 8.6 13.3 13.8 58.8 4 Excellent 27.5 
Need 
White08 26:1 33.5 49.l 35.7 40.3 184.7 0 lm_Q_rovement 46.9 
White09 31 29.9 22.8 19 15.3 118 2.6 Ve_!Y Good 38.9 
WhitelO 13.8 31.6 26.4 25.8 22.2 119.8 1.4 Fair 36.4 
Whitel 1 10.5 20.l 22.3 27.3 20.5 100.7 3 Ve_!Y Good 39.l 
White12 14.3 18.5 38 27.6 24.6 123 1.4 Fair 41.7 
Participant Resting BP Resting BP Resting BP Resting BP Resting BP Resting BP Resting BP Resting BP 
Auto LA Auto LA Auto RA Auto RA Manual LA Manual LA Manual RA Manual RA 
Systolic Diastolic Systolic Diastolic Systolic Diastolic Systolic Diastolic 
_{_mmH_g}_ 1mmH__g)_ 1mmH__g)_ _(mmH_g}_ 1mmH_g}_ 1mmHg) 1mmH_g}_ 1mmH_g}_ 
MEOl 103 65 112 69 110 70 112 72 
ME02 117 74 122 79 130 78 130 80 
ME03 102 69 101 66 96 62 108 60 
ME04 104 69 106 68 110 70 118 68 
ME05 117 68 106 65 118 74 116 72 
ME06 130 83 126 81 138 78 136 80 
ME07 141 92 151 92 144 102 154 98 
ME08 121 66 122 70 124 70 126 60 
ME09 112 75 106 74 92 68 98 68 
MElO 97 63 96 63 90 64 92 60 
MEll 108 71 104 69 98 62 104 68 
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Participant HPAPQ HPAPQ Resting Resting V02 Resting V02 V02 peak V02 peak HR Age RPE 
Score Rating HR relative absolute relative absolute max Predicted at 
(mL02·min- (L02·min-1) (mL02·min- (mL02·min- (bpm) Max HR max 
1
•kg ofB_M}_ 1•~ofB_Ml 1 _{bJ!.ml 
WhiteOl 7 Ve_!Y Good 61 3.48 242 20.90 1.44 156 154 20 
White02 11 Excellent 62 2.87 148 29.31 1.50 161 163 20 
White03 9 Excellent 62 3.12 215 26.80 1.83 168 162 14 
White04 6 Very Good 60 3.67 250 25.77 1.75 171 168 20 
White05 11 Excellent 57 3.29 210 26.05 1.69 152 164 16 
White06 11 Excellent 65 5.59 357 40.40 2.58 170 164 17 
White07 10 Excellent 81 4.08 213 29.17 1.53 147 158 18 
White08 9 Excellent 75 3.98 395 22.40 2.23 162 164 NA 
White09 11 Excellent 70 3.76 266 31.70 2.30 172 166 NA 
WhitelO 5 Good 62 3.44 262 28.15 2.14 169 165 19 
Whitel 1 10 Excellent 67 4.08 310 28.00 2.12 160 160 19 
White12 11 Excellent 64 3.29 228 23.18 1.61 175 158 11 
Participant HPAPQ HPAPQ Resting Resting V02 Resting V02 V02 peak V02 peak HR Age RPE 
Score Rating HR relative absolute relative absolute max Predicted at 
(mL02·min- (L02·min-1) (mL02·min- (mL02·min-1) (bpm) Max HR max 
1
•kg of BM) 1•kg of BM) (bpm) 
MEOl 10 Excellent 68 4.06 349 22.90 1.97 165 168 20 
ME02 11 Excellent 92 4.00 396 20.68 2.05 160 163 15 
ME03 8 Ve_ry Good 66 4.20 322 28.01 2.13 165 167 12 
ME04 10 Excellent 54 3.56 258 26.77 1.92 155 166 18 
ME05 3 Fair 72 3.50 291 19.51 1.61 146 169 20 
ME06 2 Fair 60 2.63 287 16.52 1.80 137 173 20 
ME07 2 Fair 66 2.92 298 20.17 2.06 154 171 19 
ME08 2 Fair 78 3.26 307 15.84 1.49 161 165 20 
ME09 7 Ve_!Y Good 78 5.03 244 21.29 1.45 158 167 13 
MElO 6 Ve_!Y Good 72 5.28 271 20.15 1.03 158 166 15 
MEll 7 Ve_!Y Good 91 4.45 374 24.06 2.03 177 166 16 
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Participant FORpeak Trial 1 Fatmax Trial 1 FORmax Trial 2 Fatmax Trial 2 Total Step Total EE Total Activity 
(g•min-1•kg of (% V02 peak) (g•min-1•kg of fat (% V02 peak) Count (kcal) Counts 
fat free mas~ free mas~ (steps) 
WhiteOl 8.35 45.33 7.018 48.88 9779 435.15 117583 
White02 4.385 32.75 6.082 48.74 17527 472.58 280304 
White03 7.451 49.07 7.404 37.11 7365 524.20 106604 
White04 6.439 54.83 4.613 33.33 6593 387.17 92607 
White05 8.248 55.51 9.494 49.35 9515 480 159175 
White06 17.097 63.19 16.455 62.65 23358 1183 704131 
White07 7.688 57.46 5.425 57.18 12357 472.72 260620 
White08 8.826 36.8 11.167 62.79 6177 643.47 94315 
White09 8.724 54.96 9.12 49.96 7203 581.59 142773 
WhitelO 6.88 35.23 9.21 31.88 10862 692.72 188386.67 
Whitel 1 7.403 48.85 8.879 52.99 7044 423.89 125482.67 
White12 5.247 44.6 6.516 54.6 4674 2409.37 78220.66 
FORpeak Trial 1 Fatmax Trial 1 FORmax Trial 2 Fatmax Trial 2 Total Step Total EE Total Activity 
Participant (g•min-1•kg of fat (% V02 peak) (g•min-1•kg of (% V02 peak) Count (kcal) Counts 
free massl fat free mas~ (steps) 
MEOl 7.798 31.71 8.256 28.64 7261 409.93 64343 
ME02 NA NA 14.363 43.27 8057 756.45 153845.33 
ME03 5.909 22.01 5.722 36 8701 518.95 203751 
ME04 12.973 57.57 11.33 62.75 15657 1063 284893 
ME05 8.23 52.67 8.878 66.27 2663 140.08 26785 
ME06 12.772 39.2 12.368 38.19 9362 835.94 135056 
ME07 8.364 42.1 9.665 38.63 4215 2357.79 58457 
ME08 7.197 61.85 7.662 56.09 9952 524.87 89259 
ME09 7.477 61.88 5.658 37.16 4245 380.67 120665 
MElO 3.095 34.36 3.183 45.62 4624 256.49 72626 
MEll 7.985 52.97 13.464 40.7 5917 521.73 93680 
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Participant Estradiol Estrone Progesterone Lutropin FSH Testosterone SHBG Androgen Insulin Glucose 
!I!_mol/L} !I!_mol/L} _(nmol/L} 1!![/Ll _{_ID/L} _{_nmol/L} _{_nmol/L} Index 1J!mol/L} _(noml/L} 
WhiteOl <70 208 1 37 54 2.6 57.7 0.520 47 4.9 
White02 <70 117 1 47 103 0.9 0.000 40 6.1 
White03 125 72 1 25 75 0.9 26 0.081 49 5.1 
White04 96 150 <l 36 77 1.8 50.l 0.313 22 5 
White05 169 95 1 58 101 1 47.1 0.163 47 5.8 
White06 <70 241 <l 45 136 1.6 60.7 0.337 39 4.8 
White07 <70 254 2 49 115 1.5 29.5 0.153 15 5.2 
White08 <70 152 1 32 57 1.3 33.3 0.150 97 5.4 
White09 <70 94 <l 27 50 0.9 60.l 0.188 42 5.4 
WhitelO <70 50 <l 57 93 0.69 40.5 0.097 60 6.2 
Whitel 1 <70 102 <l 21 62 0.69 25 0.060 60 5.4 
Whitel2 <70 124 1 31 97 2.1 36.9 0.269 35 4.7 
Participant Estradiol Estrone Progesterone Lutropin FSH Testosterone SHBG Androgen Insulin Glucose 
!I!_mol/L} 1J!mol/L} _{_nmol/L} _@_IL} _{ID/L} _(nmol/L} _{nmol/L} Index !I!_mol/L} _{_noml/L} 
MEOl 85 213 3 30 51 1 35.l 0.122 27 5.7 
ME02 <70 104 <l 34 64 1.1 38.7 0.148 56 4.9 
ME03 <70 <l 33 76 1.1 49.3 0.188 26 5.1 
ME04 <70 112 1 49 78 0.08 0.000 <14 4.8 
ME05 <70 186 2 36 61 1.3 24.l 0.109 87 7.3 
ME06 <70 225 2 19 37 1.8 22 0.137 128 5.4 
ME07 <70 135 1 15 35 1.9 32 0.211 183 5.6 
ME08 <70 NA <l NA NA NA NA NA 58 NA 
ME09 <70 126 1 31 75 1.6 77.7 0.431 39 4.6 
MElO <70 81 1 51 138 0.08 71.7 0.020 30 4.7 
MEll <70 176 <l 36 71 1.2 18.8 0.078 56 5.8 
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Participant Cortisol Cholesterol LDL-CH HDL-CH CHIHDL Triglycerides 
_{_nmol/Ll _(nmol/Ll _(nmol/Ll _(nmol/Ll ratio _{nmol/Ll 
MEOl 335 5.53 3.49 1.69 3.3 0.77 
ME02 124 7.15 4.56 1.63 4.4 2.12 
ME03 222 4.73 2.78 1.53 3.1 0.93 
ME04 71 4.56 2.53 1.79 2.5 0.53 
ME05 213 5.02 2.92 1.08 4.6 2.24 
ME06 166 5.18 3.47 0.88 5.9 1.83 
ME07 76 4.42 2.96 0.91 4.9 1.2 
ME08 129 NA NA NA NA NA 
ME09 269 6.95 4.1 2 3.5 1.86 
MElO 119 3.31 2.31 0.075 4.4 0.55 
MEll 367 3.98 2.1 1.23 3.2 1.24 
Participant Cortisol Cholesterol LDL-CH HDL-CH CHIHDL Triglycerides 
_(nmol/Ll _{nmol/Ll _{nmol/Ll _{nmol/L)_ ratio _{_nmol/Ll 
WhiteOl 66 9.35 6.71 1.49 6.4 2.6 
White02 198 6.04 3.52 2.1 2.9 0.92 
White03 335 4.66 3.08 1.2 3.9 0.83 
White04 104 6.01 3.99 1.4 4.3 1.36 
White05 429 5.13 2.95 1.86 2.8 0.71 
White06 256 5.97 3.94 1.5 4 1.16 
White07 1108 4.87 2.64 1.92 2.5 0.68 
White08 84 4.87 2.79 1.55 3.1 1.16 
White09 340 4.84 2.42 2.08 2.3 0.75 
WhitelO 5194 4.49 2.86 1.33 3.4 0.67 
Whitel 1 223 4.78 2.75 1.28 3.7 1.64 
White12 250 5.31 3.33 1.07 5 2 
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APPENDIX F. Data tables for the comparison of the 2nd order to the 3rd order polynomial graphs. 
Middle Eastern White 
2nd orderR 3rd orderR 2nd order 3rd order 
Partici_p_ant values values Participants R values R values 
1 0.6821 0.7876 1 0.718 0.727 
2 0.249 0.6401 2 0.8477 0.5955 
3 0.4906 0.4915 3 0.6628 0.6641 
4 0.7129 0.7734 4 0.2055 0.2061 
5 0.2591 0.3422 5 0.7693 0.779 
6 0.7808 0.8568 6 0.7493 0.9039 
7 0.8462 0.8647 7 0.6562 0.6689 
8 0.6071 0.667 8 0.1926 0.2434 
9 0.3178 0.3233 9 0.6123 0.6731 
10 0.6887 0.7124 10 0.4354 0.4945 
11 0.6116 0.6132 11 0.6086 0.6137 
12 0.4963 0.5211 
P. dS I T t F M. ddl E t W aire am_l!les es or I e as ern omen 
1 1 Sig. Paired Differences t df (2-tailed_)_ 
95% Confidence 
Std. Std. Error Interval of the 
Mean Deviation Mean Difference 
Lower UJ!I!er 
Second Order -
Third Order -0.0751 0.1108543 0.0334238 -0.149591 -0.00064 -2.247 10 0.048 
P. dS a ire I T tF Wh. W amJ!I es es or 1te omen 
Sig. 
Paired Differences t df (2-tailedl 
95% Confidence 
Std. Std. Error Interval of the 
Mean Deviation Mean Difference 
Lower U_l!l!_er 
Second Order-
Third Order -0.01135 0.0937634 0.0270672 -0.070932 0.0482161 -0.42 11 0.683 
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